

Article

The Stereochemistry of the Addition of Chlorotitanium Enolates of *N*-Acyl Oxazolidin-2-ones to 5- and 6- Membered *N*-Acyliminium Ions

Ronaldo A. Pilli*, Maria Alice Böckelmann and Conceição de Fatima Alves

Instituto de Química, Universidade Estadual de Campinas, CP 6154, 13083-970, Campinas - SP, Brazil

A adição estereosseletiva de enolatos de titânio derivados de *N*-aciloxazolidin-2-onas a ions *N*-acilimínios de 5- e 6-membros forneceu pirrolidinas 2-substituídas em proporção diastereoisomérica de moderada a boa (5:1–14:1) enquanto diastereosseletividade inferior foi observada na formação das piperidinas 2-substituídas correspondentes. O curso estereoquímico desta reação mostrou ser modulado pela natureza do ion *N*-acilimínio cíclico (5 ou 6 membros), pela natureza de seu grupo carbamato e do grupo *N*-acila presente no precursor do enolato. O modelo *lk* de aproximação parece ser dirigido pela minimização de interações de natureza não-ligante entre o grupo *N*-acila do enolato de titânio (IV) e os grupos carbamato e metilênico presentes no ion *N*-acilimínio.

The stereoselective addition of chiral and achiral titanium enolates derived from the corresponding *N*-acyl oxazolidin-2-ones to 5- and 6- membered *N*-acyliminium ions afforded 2-substituted pyrrolidines in moderate to good diastereoisomeric ratio (5:1 to 14:1) while lower diastereoselection was generally observed in the formation of the corresponding 2-substituted piperidines. The stereochemical outcome was found to be modulated by the nature of the cyclic *N*-acyliminium ion (5- or 6-membered) and of its carbamate and by the *N*-acyl group in the enolate precursor. The preferential *lk* approach seems to be dictated mainly by the minimization of non-bonding interactions between the *N*-acyl group in the chlorotitanium (IV) enolate and the carbamate and methylene groups in the cyclic *N*-acyliminium ion.

Keywords: oxazolidin-2-ones, titanium (IV) enolates, cyclic *N*-acyliminium ions, 2-substituted pyrrolidines and piperidines.

Introduction

The condensation of a carbonyl compound with an amine followed by the addition of a carbon nucleophile to the intermediate iminium species, known as the Mannich reaction, is one of the classical methods for the synthesis of β -aminocarbonyl compounds and nitrogen-containing heterocycles. The use of preformed iminium salts and carbon nucleophiles such as metal enolates, silyl enol ethers, silyl keteneacetals and enamines has greatly expanded the versatility of this reaction allowing the use of milder reaction conditions and the introduction of elements of regioselective control¹.

Despite the similarity with the aldol reaction much less is known about the structural features controlling the stereochemical outcome of the addition of prochiral carbon nucleophiles to imines or iminium ions when compared to

the corresponding addition to aldehydes. Evans and co-workers put forth a topological analysis for the addition of metallic enolates to imines based on the coordination of the nitrogen lone pair to the metallic species giving rise to chelated transition states which may adopt either chair-like or boat-like geometries depending on the interplay of steric and electronic interactions².

The utilization of *N*-acyliminium ions has attracted much attention particularly in the intramolecular version of the reaction due to their enhanced electrophilic character and the reduced bias towards Grob fragmentation displayed by the corresponding β -aminocarbonyl derivatives³. An open transition state with an antiperiplanar approach of carbon nucleophiles to the electrophilic center of the iminium ion has been proposed⁴.

Inspired by the early work of Fuentes and co-workers who first revealed the feasibility of the addition of boron enolates of chiral oxazolidin-2-ones to chiral 4-acetoxy-2-azetidiones⁵ and by the work of Nagao and co-workers

* e-mail: pilli@iqm.unicamp.br

who described the addition of tin (II) enolates of chiral 3-acyl-1,3-thiazolidine-2-thiones to 4-acetoxy-2-azetidinone and 5-acetoxy-2-pyrrolidinone⁶, we were attracted to study the effect of the ring size and the nature of the carbamoyl group of the *N*-acyliminium ion in the reactivity and stereochemical outcome of the addition of boron and chlorotitanium (IV) enolates of oxazolidin-2-ones to prochiral cyclic *N*-acyliminium ions expecting that diastereoselection would be attained due to the known facial discrimination displayed by the enolates of oxazolidin-2-ones⁷. Additionally, the results were expected to be of potential interest in the asymmetric synthesis of nitrogen heterocycles such as pyrrolizidine, indolizidine and quinolizidine ring systems⁸.

Results and Discussion


Initially, we investigated the boron enolate addition of achiral oxazolidin-2-one **1** to 2-ethoxypyrrolidine **5**, prepared by sodium borohydride reduction of an ethanolic solution of the corresponding lactam⁹. The boron enolate of achiral oxazolidin-2-one **1** was generated in CH₂Cl₂ at 0 °C upon treatment with *n*-Bu₂BOTf, according to the procedure by Evans and co-workers¹⁰, followed by the addition of **5** (1.0 equiv.) and an additional equivalent of *n*-Bu₂BOTf at 0 °C. The diastereoisomeric ratio for (+/-)-**7**:(+/-)-**8** was shown to be 13:1 after inspection of the ¹H NMR spectrum (300 MHz, 55 °C) of the crude product which displayed two doublets at δ 1.13 and δ 1.18 ppm for the methyl group at C-1' (Scheme 1)¹¹. *N*-Boc-2-substituted pyrrolidine (+/-)-**7** was isolated in 50% yield after column chromatography on silica gel. In comparison, the coupling of the *N,O*-silylketeneacetal derived from *N*-propionyl oxazolidin-2-one **1**, prepared *in situ* through the addition of 1.2 equiv. of TMSOTf and 1.15 equiv. of Et₃N in CH₂Cl₂ at 0 °C, with 2-ethoxypyrrolidine **5** was also

carried out but afforded a 2:1 mixture of (+/-)- **7** and (+/-)-**8**, in 45% yield (Table 1, entries 1 and 2).

Much to our surprise, the experimental protocol described above for the addition of the boron enolate derived from **1** to 2-ethoxypyrrolidine **5** did not provide the corresponding *N*-Boc-2-substituted piperidines (+/-)-**9**:(+/-)-**10** when 2-ethoxypiperidine **6** was added to a CH₂Cl₂ soln. of the boron enolate of oxazolidin-2-one **1**, which was recovered in almost quantitative yield, even when the reaction was carried out at room temperature and for longer reaction period. However, the reaction of 2-ethoxypiperidine **6** with the *N,O*-trimethylsilylketeneacetal of *N*-propionyl oxazolidin-2-one (**1**) did proceed to afford a 2:1 mixture of the 2-substituted piperidines corresponding to (+/-)-**9** and (+/-)-**10**, in 36% non-optimized yield after *in situ* *N*-Boc deprotection (Table 1, entries 4 and 5).

The same reactivity pattern emerged when we employed the boron enolate derived from chiral oxazolidin-2-one *ent*-**2**: ¹H NMR analysis of the crude mixture revealed that a single 2-substituted pyrrolidine was formed from **5** but no reaction was observed with 2-ethoxypiperidine **6** (Scheme 1, Table 1, entries 7 and 8). *N*-Boc pyrrolidine (+)-**11** was isolated in 55% yield after column chromatography on silica gel and had its structure established by X-ray diffraction analysis^{7b}.

As we were facing some difficulties reproducing the yields in the reactions with boron enolates¹², we decided to examine the behavior of the chlorotitanium(IV) enolates of oxazolidin-2-one **1** and **2** in the presence of cyclic *N*-acyliminium ions. Upon addition of a CH₂Cl₂ soln. of 2-ethoxypyrrolidine **5** to a previously formed solution of the chlorotitanium (IV) enolate corresponding to **1** in CH₂Cl₂ at -23 °C^{7b}, a gradual fading of the deep burgundy color of the enolate soln. was observed. ¹H NMR analysis (in CDCl₃ at 55 °C) of the crude product revealed that 2-substituted pyrrolidines (+/-)-**7** and (+/-)-**8** were produced in a 14:1



Scheme 1. a) i. ⁿBu₂BOTf, CH₂Cl₂, 0 °C, ii. DIPEA, 45min.; b) Et₃N, TMSOTf, CH₂Cl₂, 0 °C; c) i) TiCl₄, CH₂Cl₂, 0 or -23 °C ii. DIPEA, 1h; d) **5** or **6**, CH₂Cl₂.

Table 1.

Entry	Substrates ^a	Enolization Conditions	n, R ₁ , R ₂	Product	Ratio ^b	Yield ^f
1	1/5	Bu ⁿ ₂ BOTf, DIPEA	0, H, Me	7:8	13:1	50
2	1/5	TMSOTf, Et ₃ N	0, H, Me	7:8	2:1	45
3	1/5	TiCl ₄ , DIPEA	0, H, Me	7:8	14:1	72
4	1/6	Bu ⁿ ₂ BOTf, DIPEA	1, H, Me	9:10	—	—
5	1/6	TMSOTf, Et ₃ N	1, H, Me	9:10	2:1	36
6	1/6	TiCl ₄ , DIPEA	1, H, Me	9:10	—	—
7	(+)-2/5	Bu ⁿ ₂ BOTf, DIPEA	0, Bn, Me	ent-11:12	>95:5 ^c	55
8	(-)-2/5	TiCl ₄ , DIPEA	0, Bn, Me	11:12	9:1 ^{d,e}	85
9	(+)-2/6	Bu ⁿ ₂ BOTf, DIPEA	1, Bn, Me	ent-13:14	—	—
10	3/5	TiCl ₄ , DIPEA	0, H, H	15	—	46
11	3/6	TiCl ₄ , DIPEA	1, H, H	16	—	40
12	4/5	TiCl ₄ , DIPEA	0, Bn, H,	17:18	1:1 ^d	70
13	4/6	TiCl ₄ , DIPEA	1, Bn, H	19:20	3.5:1 ^e	90


^a N-acyl oxazolidin-2-one/carbamate; ^bDiastereoisomeric ratio was determined in the crude mixture by ¹H NMR spectroscopy (300 MHz) in CDCl₃ at 50°C; ^c Di-n-butyl-boron enolate derived from (+)-2 was employed; ^d Diastereoisomeric ratio was determined in the crude mixture by HPLC or GC analysis; ^eDiastereoisomers separated by flash chromatography; ^f Yields are reported after purification by column chromatography.

ratio (Scheme 1, Table 1, entry 3). Purification by column chromatography on silica gel gave (+/-)-7 in 72% yield. As before, no reaction took place when 2-ethoxypiperidine 6 was employed at -23 °C or at 0 °C (Table 1, entry 6).

The puzzling behavior of 2-ethoxypiperidine 6 led us to examine the addition of the chlorotitanium (IV) enolate derived from *N*-acetyl oxazolidin-2-one 3 which was expected to relieve steric hindrance during the approach of the nucleophile to the intermediate *N*-acyliminium ion. In fact, 2-substituted piperidine 16 was isolated in 40% yield when the reaction was carried out at -23 °C (Scheme 1, Table 1, entry 11). Under the same reaction conditions, 5 afforded 2-substituted pyrrolidine 15 in 46% yield (Scheme 1, Table 1, entry 10). In the chiral series, the reaction of chlorotitanium (IV) enolate derived from (-)-4 with 5 and 6 afforded *N*-2-substituted pyrrolidines 17:18 as a 1:1 mixture and piperidines 19:20 as a 3.5:1 mixture in 70% and 90% yield, respectively (Scheme 1, Table 1, entries 12 and 13).

At this point, it was evident that the ring size and the nature of nucleophile were modulating the reactivity and the stereochemical outcome of the reaction and an evaluation of the impact of the carbamate group of the *N*-acyliminium ion on the reaction course seemed in order. The reaction with the chlorotitanium (IV) enolate of achiral oxazolidin-2-one 1 proceeded with moderate to good yields with *N*-Cbz and *N*-CO₂Me pyrrolidines 21 and 23 and piperidines 22 and 24, but with good diastereoselection only in the pyrrolidine series (Scheme 2, Table 2, entries 1-4). The same trend was observed when the enolate of chiral oxazolidin-2-one 2 (Scheme 2, Table 2, entries 5-8) was employed and the best diastereoselection was achieved with *N*-Boc-2-ethoxypyrrolidine 5 (table 1, entries 1 and 4).

The unambiguous assignments of the absolute configuration of the major 2-substituted pyrrolidine (-)-11^{7b} and piperidine (-)-35^{7b} were achieved after X-ray diffraction analyses. The relative configurations of (+/-)-7 and (+/-)-27 were established as 2SR, 1'SR after their




Scheme 2. a) TiCl₄, CH₂Cl₂, 0 °C, DIPEA; b) TiCl₄, CH₂Cl₂, -23 °C, DIPEA; b) 21-24, CH₂Cl₂, 0 or -23 °C.

Table 2.

Entry	Oxazolidin-2-one	Carbamate	n, R ₁ , R ₂	Product	Ratio ^a	Yield ^d
1	1	21	0, H, Bn	25:26	10:1 ^b	67
2	1	22	1, H, Bn	27:28	1.6:1 ^b	50
3	1	23	0, H, Me	29:30	10:1 ^b	33
4	1	24	1, H, Me	31:32	1.2:1 ^{b,c}	70
5	(-)- 2	21	0, Bn, Bn	33:34	5:1 ^b	57
6	(-)- 2	22	1, Bn, Bn	35:36	1.8:1 ^{b,c}	50
7	(-)- 2	23	0, Bn, Me	37:38	6:1 ^b	50
8	(-)- 2	24	1, Bn, Me	39:40	1.9:1 ^b	61

^a Diastereoisomeric ratio was determined in the crude mixture by ¹H NMR spectroscopy (300 MHz) in CDCl₃ at 50°C; ^b Diastereoisomeric ratio was determined in the crude mixture by HPLC or GC analysis; ^c Diastereoisomers separated by flash chromatography; ^d Yields are reported after purification by column chromatography.


conversion to the racemic form of carboxylic acids (-)-**41** (authentic sample prepared from (-)-**11**) and **42** (authentic sample prepared from a 1.8:1 mixture of **35:36**), respectively (Scheme 3).



Scheme 3. a) LiOH, H₂O₂, THF/H₂O, 0 °C, 5h.


The relative configuration of the major products (+/-)-**25** and (+/-)-**29** formed from achiral oxazolidin-2-one **1** was confirmed to be 2SR, 1'SR after conversion of (+/-)-**7** and (+/-)-**25** to the same pyrrolidine (+/-)-**43** which upon carboxymethylation was converted to (+/-)-**29** (Scheme 4). The same protocol was employed to correlate 2-substituted piperidines (+/-)-**27** and (+/-)-**39**, after hydrogenolysis and *N*-carboxymethylation.

The relative configuration 2RS, 1'SR of the minor isomer (+)-**12** formed in the reaction of the chiral chlorotitanium




Scheme 4. a) TFA, CH₂Cl₂, 0 °C (50%); b) H₂, Pd-C, MeOH (74%); c) MeOCOCl, K₂CO₃, acetone (70%).

(IV) enolate derived from **2** and 2-ethoxypyrrolidine **5** was established after its conversion to carboxylic acid (+)-**44** (LiOH, H₂O₂, THF, H₂O, 0°C) which proved to be diastereoisomeric to carboxylic acid (-)-**41** (Scheme 5). When the major isomer (-)-**11** was treated with a THF soln. of LDA at -78°C it underwent partial epimerization at C-1' to afford (-)-**45**, a diastereoisomer of both the minor isomer (+)-**12** and the major isomer (-)-**11**, together with *N*-acyl urea **46** resulting from the nucleophilic attack of LDA to the endocyclic carbonyl of (-)-**11**. (Scheme 6).



Scheme 5. a) LiOH, H₂O₂, THF/H₂O, 0 °C, 5h (91%).




Scheme 6. a) LDA, -78 °C (**45**, 67% + **46**, 33%); b) LiOH, H₂O₂, THF/H₂O, 0 °C, 5 (91%).

Basic hydrolysis of (-)-**45** afforded carboxylic acid (-)-**44** which was shown to be enantiomeric to the carboxylic acid (+)-**44** obtained from the basic hydrolysis of (+)-**12** thus confirming the 2R, 1'S stereochemistry of the later carboxylic acid. (Schemes 5 and 6)

The absolute configuration of the major and minor pyrrolidines in the mixture **33:34** was assigned after conversion of a 9:1 mixture of **11:12** into a 9:1 mixture of **33:34** which involved Boc removal ($\text{CF}_3\text{CO}_2\text{H}$, CH_2Cl_2 , rt) and nitrogen protection (ClCO_2Bn , K_2CO_3 , CH_2Cl_2). The stereochemistries of pyrrolidines **37** and **38** were determined accordingly.


In the piperidine series, X-ray diffraction analysis established the stereochemistry of the major adduct (-)-**35**^{7b}, and the absolute configuration of the minor isomer (-)-**36** was eventually established as 2R, 1'S after its conversion to piperidine derivative (+)-**49**, enantiomeric to the piperidine derivative obtained from (-)-**35** (Scheme 7).



Scheme 7. a) NaBH_4 , THF, H_2O , 16h (70%); b) i. TsCl , Et_3N , DMAP (70%); ii. 1. NaI , DME, 80 °C; 2. $^t\text{Bu}_3\text{SnH}$, 1h (60%).

Inspection of the ^{13}C NMR spectra in the 2-substituted piperidines series revealed a downfield shift of C-2 in the major isomers when compared with the minor ones ($\Delta\delta$ 1.4-1.7 ppm) which may be diagnostic of their relative stereochemistry. The absolute configuration of **39:40** was confirmed after conversion of a 1.8:1 mixture of (-)-**35** and (-)-**36** of known configuration to the corresponding mixture of **39:40** (i. H_2 , Pd/C, MeOH, rt; ii. MeOCOC l, K_2CO_3 , acetone, rt) and comparison by HPLC analysis.

Finally, the major isomer (-)-**19** formed in the addition of the chlorotitanium (IV) enolate derived from oxazolidin-2-one (-)-**4** to 2-ethoxy piperidine **6** was shown to have 2S configuration after its conversion to the known methyl ester (-)-**51** (Scheme 8)¹³.




Scheme 8. a) i. LiOH , H_2O_2 , H_2O , THF, 0 °C, 5h (85%); b) CH_2N_2 , Et_2O (95%).

In order to extend the study of the influence of the nature of the nucleophile in the stereochemical outcome of the reaction, chlorotitanium (IV) enolates derived from oxazolidin-2-ones **52** and **53** were employed (Scheme 9). Our choice was additionally guided by the potential usefulness of the corresponding adducts in the asymmetric synthesis of (2R, 2'R)-methylphenidate hydrochloride^{7c} and in the total synthesis of pyrrolizidine and indolizidine alkaloids⁶.

As depicted in Table 3 the formation of 2-substituted pyrrolidine derivatives occurred with excellent diastereoselection (>95:5, entries 1, 4 and 5) while moderate to good selectivity was observed in the piperidines series (entries 2, 3 and 6), superior to the diastereoisomeric ratio observed with chlorotitanium enolates from oxazolidin-2-ones **1-4** (Table 1 and 2). The absolute configuration for **54**, **60** and **62** was tentatively assigned as (2R, 1'R) based on our previous results for the addition of chlorotitanium enolates derived from **2** to α -alkoxy pyrrolidines **5**, **21** and **23**.

Inspection of the ^{13}C NMR spectra of the mixture **64:65** revealed that the major isomer **64** displayed its C-2 shift downfield (1.4 ppm) in comparison with the minor isomer



Scheme 9. a) i. TiCl_4 , CH_2Cl_2 , 5 min., -23 °C; ii. DIPEA, 1h; b) **5**, **21**, **22** or **24**, CH_2Cl_2 .

Table 3.

Entry	Oxazolidin—2-one	Carbamate	n, R, R ¹	Products	ratio	Yield (%) ^b
1	52	5	0, Ph, ¹ Bu	54:55	>95:5 ^a	70
2	52	22	1, Ph, Bn	56:57	12:1 ^{a,c}	60
3	52	24	1, Ph, Me	58:59	8:1 ^{a,d,e}	73
4	53	5	0, (CH ₂) ₃ Cl, ¹ Bu	60:61	>95:5 ^a	81
5	53	21	0, (CH ₂) ₃ Cl, Bn	62:63	>95:5 ^a	73
6	53	22	1, (CH ₂) ₃ Cl, Bn	64:65	4:1 ^{b,f}	60

^a Diastereoisomeric ratio was determined in the crude mixture by ¹H NMR spectroscopy (300 MHz) in CDCl₃ at 55°C; ^b Yields are reported after purification of the crude mixture by column chromatography; ^c Diastereoisomeric ratio was determined in the crude mixture by HPLC analysis; ^d Diastereoisomeric ratio was determined in the crude mixture by GC analysis; ^e Major diastereoisomer recrystallized from ethyl acetate-hexane; ^f Diastereoisomers separated by flash chromatography.

65, as observed earlier for 2-substituted piperidines depicted in Table 2. Based on that evidence (2R, 1'R) and (2R, 1'S) configuration were assigned to **64** and **65**, respectively.

The absolute configuration of the majors isomers **56** and **58** was established after their conversion to (2R, 2'R) methylphenidate hydrochloride (**66**). Methylphenidate is a mild psychostimulant and is widely prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) in children, a condition that is manifested by impulsivity, hyperactivity, and inattention. It is marketed as its racemic form despite the fact that the 2R, 2'R-isomer is several times more active than the corresponding enantiomer¹⁴⁻¹⁶.


Basic hydrolysis of the mixture **56/57** allowed the efficient recovery of the chiral auxiliary (>90% yield), and provided carboxylic acid **67** which was converted to methyl ester **68** in 81% overall yield, as a 12:1 mixture with its 2'S epimer. Hydrogenolysis followed by treatment with ethanolic HCl, and recrystallization from EtOH/Et₂O afforded (+)-(2R, 2'R)-methylphenidate hydrochloride **66** in 76% yield from **67**.

Alternatively, basic hydrolysis of **58** allowed recovery of the chiral auxiliary (90% yield), and afforded carboxylic acid **69** in 90% yield. Carbamate deprotection was accomplished with *in situ* prepared trimethylsilyl iodide and it was followed by esterification and treatment with ethanolic HCl to provide (2R, 2'R)-methylphenidate hydrochloride **66** in 63% yield from **69**.

Overall, (2R, 2'R)-methylphenidate hydrochloride **66** was prepared in 4 steps and 43% overall yield from **22** and in 5 steps and 37% overall yield from **24** (Scheme 10).

The absolute configuration (2S, 1'R) for the minors isomers **57** and **59** was assigned based on our previous studies (Scheme 2, Table 2) in agreement with the results by Matsumura et al^{7c}.


From the body of information described above it emerges that the oxazolidin-2-one moiety is efficiently discriminating its approach to the *N*-acyliminium ion: in



Scheme 10. a) from **56**: i. LiOH, H₂O₂, THF/H₂O, 0 °C; ii. CH₂N₂, Et₂O, rt (81%); b) from **58**: LiOH, H₂O₂, THF/H₂O, 0 °C (90%); c) from **68**: i. Pd-C, MeOH, H₂; ii. 2N HCl, EtOH (76%, 2 steps); d) from **69**: i. Me₃SiI, CH₂Cl₂, 0 °C; ii. CH₂N₂, Et₂O, rt; iii. 2N HCl, EtOH (63%, 3 steps)

every case, both major and minor isomers displayed 1'S stereochemistry when (R)-4-benzyl oxazolidin-2-one was employed as chiral auxiliary revealing the preferential approach of the *Re* face of the corresponding chlorotitanium (IV) enolate. A *Z*-configured internally coordinated chlorotitanium (IV) enolate, as depicted in Scheme 11, is proposed to be the nucleophilic species in the reactions above and either an antiperiplanar or a synclinal approach of the nucleophile to the *N*-acyliminium ion seems to be available.

For bulky carbamates such as **5-6** (Scheme 1) the stereochemical outcome will be dictated by the relief of steric interactions involving the Boc group: while this seems to be the case for the antiperiplanar approach to *Re* face of the *N*-acyliminium ion (see A, Scheme 11), the synclinal approach to the *Re* face of the electrophilic species brings Boc and oxazolidin-2-one groups into close proximity (see B, Scheme 11). Despite keeping Boc and oxazolidin-2-one groups apart, the antiperiplanar approach of chlorotitanium (IV) enolate to the *Si* face of the *N*-acyliminium ion develops non-bonding interactions between Boc and R₂ groups (see C, Scheme 11). A sterically



Scheme 11.

congested synclinal approach such as depicted in D (Scheme 11) seems to be of only marginal relevance in the reaction manifold due *inter alia* to steric hindrance involving the titanium (IV) ligands and Boc group.

The steric interactions involving R₂ group and cyclic *N*-acyliminium ion are not, however, to be overlooked (see A and D, Scheme 11) particularly when cyclic 6-membered *N*-acyliminium ions are involved. The preferred half-chair conformation in these cases will bring about significant non-bonding interactions during the approach of the nucleophile which are partially relieved when more flattened cyclic 5-membered *N*-acyliminium ions are involved. Not surprisingly, no reaction was observed between the *N*-acyliminium ion derived from **6** and boron enolates prepared from **1** and (+)-**2** or chlorotitanium (IV) enolates derived from **1** and **2**, even at room temperature and longer reaction periods.

The reactivity was restored when *N*-acyl chlorotitanium (IV) enolates derived from **3** and **4** were employed in the reaction with **6** affording **16** (40% yield) and **19:20** (90% yield, 3.5:1 ratio). The higher diastereoselectivity observed in the reaction of **4** and **6** (3.5:1 ratio) when compared to the corresponding reaction with **5** (1:1 ratio) may be due to steric hindrance between the half-chair conformation of **6** and the oxazolidinone ring thus disfavoring approach C (Scheme 11).

According to the transition state model depicted in Scheme 11, utilization of less sterically demanding

carbamates such as **21-24** resulted in lower levels of diastereoselection when compared to the ones observed for *N*-Boc carbamate **5** while keeping the preference for *lk* topology¹⁷. The diastereoisomeric ratios observed for the *N*-CO₂Me and *N*-CO₂Bn 2-alkoxycarbamates did not vary significantly.

The higher levels of diastereoselection observed in the reaction of the chlorotitanium enolate derived from (*S*)-**52** with **22** and **24** contrasts with those found for (*R*)-**2** and point out either to a relief of steric interaction upon changing a methyl group in the chlorotitanium enolate derived from **52** (A, Scheme 11) or to a synclinal approach as depicted in B (Scheme 11). In both cases, the *lk* topology¹⁷ would be greatly favoured resulting in the preferential formation of **56** and **58**. Additionally the *s-cis/s-trans* orientation of the carbamate group and the stereoelectronics associated with 6-membered *N*-acyliminium ions may be relevant to rationalize these results.

The stereochemical outcome observed in the reaction of the di-*n*-butylboron enolate from *ent*-**2** with 2-ethoxypyrrolidine **5** (Scheme 1), which occurred with the same *lk* topology as observed for the chlorotitanium (IV) enolate from **2**, do not support the coordination of the *N*-acyliminium carbamate group to the *Z*-configured internally coordinated chlorotitanium (IV) enolate, as proposed by Matsumura and co-workers^{7c}.

Conclusions

The stereochemical outcome of the addition of chlorotitanium (IV) enolates derived from *N*-acyloxazolidin-2-ones to *in situ* generated cyclic *N*-acyliminium ions was shown to be dependent on the nature of the ring size and carbamate group in the *N*-acyliminium ion and on the *N*-acyl group in the chlorotitanium (IV) enolate: 5-membered *N*-acyliminium ions derived from **5**, **21** and **23** reacted with the chlorotitanium (IV) enolate derived from *N*-propionyl oxazolidinones **1** and **2** with moderated to good diastereoisomeric ratio (5:1-14:1) but poor diastereoselection was observed when the *N*-acyliminium ions generated from 6-membered piperidines **22** and **24** were employed. Better yield and selectivities were observed for the BOC protected *N*-acyliminium ion derived from **5** when compared to the corresponding *N*-carbobenzyloxy and *N*-carbomethoxy analogues but *N*-Boc-2-ethoxy piperidine **6** failed to react with the chlorotitanium (IV) enolates derived from **1** and **2**.

The preferential *lk* approach observed was rationalized based on the minimization of steric interactions involving the *N*-acyl group in the chlorotitanium (IV) enolate and carbamate and methylene groups in the cyclic *N*-acyliminium ions.

The reaction of *N*-acyliminium ions derived from **5**, **22** and **24** with the chlorotitanium (IV) enolate derived from (*S*)-*N*-phenylacetyloxazolidinone **52** provided 2-substituted pyrrolidine **54** (70% yield, >95:5 d.r.) and 2-substituted piperidines **56** (60% yield, 12:1 d.r.) and **58** (73% yield, 8:1 d.r.) which were converted to (2*R*, 2'*R*)-methylphenidate hydrochloride in 4 steps and 62% and 57% overall yield, respectively. Studies are underway aiming to employ the adducts obtained from *N*-acyl oxazolidin-2-one **53** in the asymmetric total synthesis of pyrrolizidine and indolizidine alkaloids.

Experimental Section

Infrared spectra were recorded on a Nicolet Impact 410 spectrometer and ¹H- and ¹³C NMR spectra were measured on a Bruker AC-300P (7.0T), VARIAN GEMINI (7.0T) or VARIAN INOVA (11.7T) spectrometers. Chemical shifts are reported in parts per million downfield from tetramethylsilane internal standard. Data are reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qt = quintet, m = multiplet, br = broad) and coupling constants. Chemical shifts of ¹³C NMR spectra are reported in ppm from tetramethylsilane using the solvent resonance as internal standard (deuteriochloroform: 77.0 ppm, deuteromethanol: 49.0 ppm). NMR data for mixture of diastereoisomers are reported with the

chemical shift of the minor diastereoisomer following the one of the major isomer. The optical rotation was measured on a Polamat A (Carl Zeiss) or Perkin Elmer 241 polarimeter. Mass spectra were obtained in the electron impact (EI) mode using an HP-5890-serie II chromatograph equipped with HP-1 column (25m x 0.20mm x 0.33μm) or Ultra 2 column (25m x 0.20mm x 0.33μm) coupled to a HP-5988 mass detector and high resolution mass spectra on a VG Autospec/Fission Instrument. HPLC analyses were performed with HP1050 chromatograph equipped with Hypersil column (5μm, 200 x 4,6mm). Melting points were measured in open capillary tubes using an Electrothermal 9100 apparatus and are not corrected. Elemental analyses were carried on a Perkin Elmer-2400 series II CHNS/O analyser. Column chromatography was performed with Aldrich silica gel (70-230 mesh) and flash chromatograph with Merck silica gel 60 (230-400 Mesh). Thin-layer chromatography (TLC) was carried out on Alugram[®] SIL G/UV₂₅₄ precoated plates and were developed with potassium permanganate in all cases. Unless otherwise noted, all reactions were conducted in flame-dried glassware with magnetic stirring under an inert atmosphere of dry nitrogen or argon. Solvents and reagents were purified and dried when necessary using standard procedures¹⁸.

Starting Materials

The achiral *N*-acyloxazolidinones derivatives **1** and **3**¹⁹, the chiral ones **2**, **4**, **52** and **53**²⁰, α -ethoxycarbamates **5** and **6**^{9a,b} and α -methoxycarbamates **21-24**²¹ were prepared according to published procedures.

General procedure for the addition of the *N,O*-silylketeneacetal from **1** to cyclic *N*-acyliminium ions

To a solution of **1** (0.090 g, 0.62 mmol) in CH₂Cl₂ (3.0 cm³) at 0 °C was added Et₃N (0.12 cm³, 0.87 mmol), and TMSOTf (0.14 cm³, 0.74 mmol) dropwise. The resulting homogeneous solution was stirred for 45 min at 0 °C. The solution was cooled to -78 °C, and the α -alkoxycarbamate **5** or **6** (0.57 mmol) was added, followed by catalytic amount of TMSOTf. After 2 h the reaction was quenched with satd. aq. NH₄Cl (5.0 cm³) and extracted with CH₂Cl₂ (3 x 5 cm³). The combined organic layer was dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure.

(2*SR*, 1'*SR*) and (2*RS*, 1'*SR*) *tert*-Butyl 2-[2'-(2-oxo-1,3-oxazolan-3-yl)-1'-methyl-2'-oxoethyl]-1-azolane-carboxylate (**7/8**)

The product was purified by chromatography on silica

gel (impregnated with Et₃N, 20% ethyl acetate-hexane) to provide a 2:1 mixture of **7:8** (0.087 g, 45%; determined by ¹H NMR analysis) as a colorless solid. IR $\nu_{\max}/\text{cm}^{-1}$ 1778, 1699; ¹H NMR (300 MHz; 60 °C; CDCl₃) δ 1.13 and 1.18 (d, *J* 6.7 and 7.0 Hz, respectively, 3H), 1.43 and 1.44 (s, 9H), 1.55-2.00 (m, 4H), 3.21-3.31 (m, 1H), 3.42-3.52 (m, 1H), 3.98-4.09 (m, 3H), 4.09-4.20 (m, 1H), 4.25-4.40 (m, 2H); ¹³C NMR (75.5 MHz; 60 °C; CDCl₃) δ 13.4, 23.5, 28.4 and 28.5, 28.9, 40.0 and 41.0, 43.1, 47.0, 60.5 and 59.5, 61.7, 79.3, 153.3, 154.9 and 155.0, 175.4; MS (EI): *m/z* 211 (25%), 195 (7%), 170 (10%), 143 (9%), 124 (24%), 115 (6%), 114 (48%), 88 (17%), 70 (100%), 69 (10%), 57 (82%); HRMS (EI): found 312.1688; calc. for C₁₅H₂₄N₂O₅ [M]⁺ 312.1685.

(2SR, 1'SR) and (2RS, 1'SR) - 2-[2'-(2-oxo-1,3-oxazolan-3-yl)-1'-methyl-2'-oxoethyl]-1-piperidine (9/10)

The product was purified by chromatography on silica gel (5% methanol-chloroform with a few drops of NH₄OH) to provide a 2:1 mixture of the corresponding *N*-deprotected form of **9:10** (0.050 g, 36%; determined by ¹H NMR analysis) as a colorless oil. IR $\nu_{\max}/\text{cm}^{-1}$ 3453, 1706, 1658; ¹H NMR (300 MHz; CDCl₃) δ 1.19 and 1.28 (d, *J* 7.3 and 7.0 Hz, respectively, 3H), 1.38-1.58 (m, 2H), 1.58-1.80 (m, 2H), 1.80-2.05 (m, 2H), 2.60-2.82 (m, 2H), 2.82-3.01 and 3.01-3.18 (m, 1H), 3.25-3.42 (m, 1H), 3.62-3.80 (m, 2H), 3.92-4.06 (m, 1H), 4.06-4.20 (m, 1H), 4.10-4.22 (m, 1H); ¹³C NMR (75.5 MHz; CDCl₃) δ 10.6 and 13.6, 23.6 and 24.2, 25.7, 32.0, 41.7 and 38.7, 43.7, 47.4, 57.8 and 57.2, 62.3, 154.9 and 155.3, 173.1; HRMS (EI): found 227.1400; calc. for C₁₁H₁₉N₂O₃ [MH]⁺ 227.1390.

General procedure for the addition of the titanium enolates of N-acyloxazolidinones to cyclic N-acyliminium ions

To a solution of TiCl₄ (0.12 cm³, 1.1 mmol) in CH₂Cl₂ (2.0 cm³) at temperature T1 was added dropwise a solution of *N*-acyloxazolidinone (1.0 mmol) in CH₂Cl₂ (2.8 cm³). After 5 min., diisopropylethylamine (0.20 cm³, 1.1 mmol) was added and the mixture was stirred 1h at temperature T1. The reaction mixture was cooled to temperature T2 and a solution of α -alkoxycarbamate (1.1 mmol) in CH₂Cl₂ (4.8 cm³) was added dropwise. The mixture was then stirred 1 h at temperature T2 and the reaction was quenched with satd. aq. NH₄Cl (5.0 cm³) and extracted with CH₂Cl₂ (3 x 5 cm³). The combined organic layer was dried over MgSO₄, filtered and the solvent was evaporated under reduced pressure.

The reaction temperatures (T1, T2), purification, yield, spectral and analytical data of the adducts prepared are as follows.

(2SR, 1'SR) and (2RS, 1'SR) tert-Butyl 2-[2'-(2-oxo-1,3-oxazolan-3-yl)-1'-methyl-2'-oxoethyl]-1-azolanecarboxylate (7/8)

Reaction temperatures T1 = T2 = -23 °C. The product was purified by chromatography on silica gel (impregnated with Et₃N, 20% ethyl acetate-hexane) to provide a 14:1 mixture of **7:8** (0.22 g, 72%; determined by ¹H-NMR analysis) as a colorless solid. Data for **7**: mp 57 °C; IR $\nu_{\max}/\text{cm}^{-1}$ 1778, 1699; ¹H NMR (300 MHz; 60 °C; CDCl₃) δ 1.13 (d, *J* 6.7 Hz, 3H), 1.43 (s, 9H), 1.70-2.00 (m, 4H), 3.21-3.31 (m, 1H), 3.42-3.52 (m, 1H), 3.98-4.09 (m, 3H), 4.09-4.20 (m, 1H), 4.25-4.40 (m, 2H); ¹³C NMR (75.5 MHz; 60 °C; CDCl₃): δ 13.4, 23.5, 28.4, 28.9, 40.0, 43.1, 47.0, 60.5, 61.7, 79.3, 153.3, 154.9, 175.4; MS (EI): *m/z* 211 (25%), 195 (7%), 170 (10%), 143 (9%), 124 (24%), 115 (6%), 114 (48%), 88 (17%), 70 (100%), 69 (10%), 57 (82%); HRMS (EI): found 312.1688; calc. for C₁₅H₂₄N₂O₅ [M]⁺ 312.1685.

(2S, 1'S) and (2R, 1'S) tert-Butyl 2-{2'-[(4R)-4-benzyl-2-oxo-1,3-oxazolan-3-yl]-1'-methyl-2'-oxoethyl]-1-azolanecarboxylate (11/12)

Reaction temperatures T1 = 0 °C, T2 = -23 °C. The product was purified by chromatography on silica gel (impregnated with Et₃N, 20% ethyl acetate-hexane) to afford a 9:1 mixture of **11** and **12** (0.34 g, 85%; determined HPLC and ¹H NMR analysis) as an oil. The isomers were separated by flash chromatography on silica gel (impregnated with Et₃N, 12% ethyl acetate-hexane). Found: C, 65.81; H, 7.45; N 7.06. Calc. for C₂₂H₃₀N₂O₅ C, 65.65; H, 7.51; N, 6.96%. Data for **11**: colorless solid; mp 178-179 °C; [α]_D²⁰ -40.4 (c 1.4, CH₂Cl₂); IR $\nu_{\max}/\text{cm}^{-1}$ 1782, 1691; ¹H NMR (300 MHz; 60 °C; CDCl₃) δ 1.13 (d, 3H, *J* 6.5 Hz), 1.45 (s, 9H), 1.77-1.88 (m, 1H), 1.88-1.98 (m, 3H), 2.63 (dd, *J* 10.2 and 13.4 Hz, 1H), 3.26-3.32 (m, 1H), 3.40-3.60 (m, 2H), 4.05-4.20 (m, 2H), 4.20-4.38 (m, 2H), 4.60-4.70 (m, 1H), 7.19-7.35 (m, 5H); ¹³C NMR (75.5 MHz; 60 °C; CDCl₃) δ 12.4, 24.0, 28.4, 28.7, 38.3, 40.7, 47.3, 55.8, 58.9, 66.2, 79.6, 127.3, 129.0, 129.4, 136.2, 154.1, 154.9, 175.5. Data for **12**: colorless oil [α]_D²⁰ +0.90 (c 1.4, CH₂Cl₂); IR $\nu_{\max}/\text{cm}^{-1}$ 1777, 1694; ¹H NMR (300 MHz; 50 °C; CDCl₃) δ 1.21 (d, *J* 6.6 Hz, 3H), 1.47 (s, 9H), 1.74-2.12 (m, 4H), 2.69 (dd, *J* 10.0 and 13.4, 1H), 3.20-3.38 (m, 1H), 3.38-3.62 (m, 2H), 3.92-4.08 (m, 1H), 4.08-4.22 (m, 2H), 4.22-4.42 (br m, 1H), 4.62-4.74 (m, 1H), 7.16-7.40 (m, 5H); ¹³C NMR (75.5 MHz; 50 °C; CDCl₃) δ 13.9, 23.3, 28.3, 29.7, 38.0, 41.4, 45.7, 55.4, 59.5, 66.1, 79.4, 127.4, 129.1, 129.6, 136.0, 153.5, 155.5, 176.2.

tert-Butyl 2-[2'-(2-oxo-1,3-oxazolan-3-yl)-2'-oxoethyl]-1-azolanecarboxylate (15)

Reaction temperatures T1 = T2 = -23 °C. The product was purified by chromatography on silica gel (impregnated with Et₃N, 30% ethyl acetate-hexane) to provide **15** (0.14 g, 46%) as an oil. IR $\nu_{\max}/\text{cm}^{-1}$ 1780, 1693; ¹H NMR (300 MHz; 50 °C; CDCl₃) δ 1.44 (s, 9H), 1.60-1.74 (m, 1H), 1.76-1.90 (m, 2H), 2.02-2.19 (m, 1H), 3.05 (dd, *J* 7.8 and 16.0 Hz, 1H) 3.18-3.42 (m, 3H), 3.94-4.10 (m, 2H), 4.25-4.46 (m, 3H); ¹³C NMR (75.5 MHz; 50 °C; CDCl₃) δ 23.3, 28.5, 31.6, 40.0, 42.6, 46.3, 53.9, 62.0, 79.3, 154.4, 154.5, 171.3; MS (EI) *m/z*: 243 (7%), 242 (12%), 225 (8%), 199 (6%), 198 (7%), 197 (63%), 181 (6%), 156 (7%), 154 (6%), 139 (6%), 127 (5%), 114 (28%), 110 (53%), 101 (5%), 88 (12%), 84 (5%), 83 (15%), 82 (6%), 71 (6%), 70 (100%), 69 (5%), 68 (7%), 67 (6%), 57 (68%), 56 (6%), 55 (9%); HRMS (EI): found 298.1529; calc. for C₁₄H₂₂N₂O₅ [M]⁺ 298.1529.

tert-Butyl 2-[2'-(2-oxo-1,3-oxazolan-3-yl)-2'-oxoethyl]-1-piperidinecarboxylate (16)

Reaction temperatures T1 = T2 = -23 °C. The product was purified by chromatography on silica gel (impregnated with Et₃N, 30% ethyl acetate-hexane) to provide **16** (0.12 g, 40%) as an oil. IR $\nu_{\max}/\text{cm}^{-1}$ 1772, 1690; ¹H NMR (300 MHz; 60 °C; CDCl₃) δ 1.43 (s, 9H) 1.40-1.70 (m, 6H), 2.92 (br t, *J* 13.1 Hz, 1H), 3.05 (dd, *J* 9.0 and 14.0 Hz, 1H), 3.29 (dd, *J* 5.6 and 14.0, 1H), 3.87-4.03 (m, 3H), 4.30-4.40 (m, 2H), 4.77-4.85 (m, 1H); ¹³C NMR (75.5 MHz; 60 °C; CDCl₃) δ 19.2, 25.4, 28.6, 29.3, 35.9, 39.6, 42.7, 47.9, 62.1, 79.4, 153.7, 155.1, 171.2; MS (EI): *m/z* 211 (30%), 184 (7%), 129 (21%), 128 (69%), 124 (12%), 101 (12%), 88 (15%), 84 (100%), 83 (7%), 57 (46%), 55 (7%); HRMS (EI): found 312.1685; calc. for C₁₅H₂₄N₂O₅ [M]⁺ 312.1685.

(2S) and (2R) tert-Butyl 2-[2'-(4R)-4-benzyl-2-oxo-1,3-oxazolan-3-yl]-2'-oxoethyl]-1-azolanecarboxylate (17/18)

Reaction temperatures T1 = 0 °C and T2 = -23 °C. The product was purified by chromatography on silica gel (impregnated with Et₃N, 15% ethyl acetate-hexane) to afford a 1:1 mixture of **17** and **18** (0.27 g, 70%; determined by HPLC and ¹H NMR analysis) as an oil. IR $\nu_{\max}/\text{cm}^{-1}$ 1778, 1703; ¹H NMR (300 MHz; 55 °C; CDCl₃) δ 1.44 and 1.45 (9H, s, C(CH₃)₃), 1.59-1.75 (m, 1H), 1.77-2.00 (m, 2H), 2.00-2.20 (1H, m, CHH-3), 2.77 and 2.76 (dd, *J* 13.5/9.7 and 12.9/9.6 Hz, 1H), 2.91-3.08 and 3.08-3.25 (m, 1H), 3.25-3.45 (m, 4H), 4.10-4.20 (m, 2H), 4.25-4.41 (m, 1H), 4.58-4.72 (m, 1H), 7.15-7.35 (m, 5H); ¹³C NMR (75.5 MHz; 60 °C; CDCl₃) δ 23.4 and 23.1, 28.6, 31.7 and

31.9, 38.2 and 38.3, 40.2 and 40.7, 46.4 and 46.5, 53.8 and 54.2, 55.3 and 55.4, 66.4, 79.4, 127.3, 129.0, 129.5, 135.7, 153.6, 154.5, 171.5 and 171.3; MS (EI): *m/z* 332 (5%), 315 (5%), 288 (13%), 287 (56%), 178 (7%), 156 (8%), 117 (8%), 114 (22%), 110 (73%), 91 (23%), 86 (6%), 83 (12%), 70 (100%), 68 (9%), 67 (5%), 57 (64%), 55 (7%); HRMS (EI): found 388.1997; calc. for C₂₁H₂₈N₂O₅ [M]⁺ 388.1998.

(2S) and (2R) tert-Butyl 2-[2'-(4R)-4-benzyl-2-oxo-1,3-oxazolan-3-yl]-2'-oxoethyl]-hexahydro-1-pyridinecarboxylate (19/20)

Reaction temperatures T1 = T2 = -23 °C. The product was purified by chromatography on silica gel (30% ethyl acetate-hexane) to afford a 3.5:1 mixture of **19** and **20** (0.36 g, 90%; determined ¹H NMR analysis) as an oil. The isomers were separated by flash chromatography on silica gel (15% ethyl acetate-hexane). MS (EI): *m/z* 219 (56%), 149 (21%), 134 (25%), 128 (94%), 124 (31%), 117 (6%), 116 (7%), 92 (17%), 91 (61%), 86 (78%), 84 (100%), 83 (7%), 65 (15%), 57 (59%); HRMS (EI): found 301.1551; calc. for C₁₇H₂₁N₂O₃ [M-C₅H₉O₂]⁺ 301.1552. Data for **19**: colorless oil; [α]_D²⁰ -75.0 (*c* 1.5, CH₂Cl₂); IR $\nu_{\max}/\text{cm}^{-1}$ 1782, 1689; ¹H NMR (300 MHz; 60 °C; CDCl₃) δ 1.43 (s, 9H), 1.50-1.74 (m, 6H), 2.77 (dd, *J* 9.5 and 13.6 Hz, 1H), 2.94 (br t, *J* 13.6 Hz, 1H), 3.07 (dd, *J* 9.2 and 14.3 Hz, 1H), 3.29 (dd, *J* 2.9 and 15.0 Hz, 1H), 3.32 (dd, *J* 5.9 and 14.3 Hz, 1H), 3.98 (br d, *J* 15.4 Hz, 1H), 4.11 (dd, *J* 2.9 and 8.8 Hz, 1H), 4.22 (t, *J* 8.4 Hz, 1H), 4.52-4.64 (m, 1H), 4.78-4.90 (m, 1H), 7.14-7.20 (m, 2H), 7.20-7.34 (m, 3H); ¹³C NMR (75.5 MHz; 60 °C; CDCl₃) δ 19.1, 25.3, 28.4, 29.1, 36.2, 38.1, 39.6, 47.7, 55.4, 66.2, 79.3, 127.2, 128.9, 129.3, 135.6, 153.6, 155.0, 171.0; Data for **20**: colorless solid; mp 111.9-112.7 °C; [α]_D²⁰ -38.3 (*c* 1.1, CH₂Cl₂); IR $\nu_{\max}/\text{cm}^{-1}$ 1784, 1691; ¹H NMR (300 MHz; 50 °C; CDCl₃) δ 1.43 (s, 9H), 1.50-1.70 (m, 6H), 2.77 (dd, *J* 9.5 and 13.6 Hz, 1H), 2.94 (br t, *J* 13.0 Hz, 1H), 3.07 (dd, *J* 9.5 and 13.7 Hz, 1H), 3.32 (dd, *J* 2.9 and 13.6 Hz, 1H), 3.33 (dd, *J* 5.7 and 14.3 Hz, 1H), 3.98 (br d, *J* 14.3 Hz, 1H), 4.11 (dd, *J* 2.8 and 9.0 Hz, 1H), 4.22 (br t, *J* 8.3 Hz, 1H), 4.52-4.62 (m, 1H), 4.76-4.90 (m, 1H), 7.14-7.20 (m, 2H), 7.20-7.34 (m, 3H); ¹³C NMR (75.5 MHz; 50 °C; CDCl₃) δ 19.1, 25.3, 28.4, 29.0, 36.2, 38.1, 39.6, 47.6, 55.4, 66.2, 79.3, 127.2, 128.9, 129.3, 135.6, 153.7, 155.0, 171.0.

(2SR, 1'SR) and (2RS, 1'SR) Benzyl 2-[2'-(2-oxo-1,3-oxazolan-3-yl)-1'-methyl-2'-oxoethyl]-1-azolanecarboxylate (25/26)

Reaction temperatures T1 = T2 = -23 °C. The product was purified by chromatography on silica gel (impregnated

with Et₃N, 30% ethyl acetate-hexane) to afford a 10:1 mixture of **25** and **26** (0.23 g, 67%; determined by HPLC analysis) as an oil. Found: C, 62.47; H, 6.00; N, 8.17. Calc. for C₁₈H₂₂N₂O₅ C, 62.42; H, 6.40; N, 8.09%. IR $\nu_{\max}/\text{cm}^{-1}$ 1777, 1700; Data for **25**: ¹H NMR (300 MHz; 55 °C; CDCl₃) δ 1.11 (d, *J* 6.2 Hz, 3H), 1.74-1.86 (m, 1H), 1.86-2.04 (m, 3H), 3.30-3.42 (m, 1H), 3.42-3.54 (m, 1H), 3.64-3.78 (m, 1H), 3.87 (qt, *J* 9.0 Hz, 1H), 3.90-4.03 (m, 1H, CH-2), 4.04-4.14 (m, 2H), 4.14-4.28 (m, 1H), 5.03 (d, *J* 12.5 Hz, 1H), 5.11 (d, *J* 12.5 Hz, 1H), 7.22-7.40 (m, 5H); ¹³C NMR (75.5 MHz; 55 °C; CDCl₃) δ 13.2, 23.3, 28.7, 39.8, 42.9, 46.9, 60.4, 61.6, 66.6, 127.9, 128.0, 128.4, 137.1, 153.4, 155.3, 175.3.

(2*SR*, 1'*SR*) and (2*RS*, 1'*SR*) Benzyl 2-[2'-(2-oxo-1,3-oxazolan-3-yl)-1'-methyl-2'-oxoethyl]-1-piperidine-carboxylate (**27/28**)

Reaction temperatures T1 = T2 = -23 °C. The product was purified by chromatography on silica gel (impregnated with Et₃N, 30% ethyl acetate-hexane) to afford a 1.6:1 mixture of **27** and **28** (0.18 g, 50%; determined by HPLC and ¹H NMR analysis) as an oil. IR $\nu_{\max}/\text{cm}^{-1}$ 1778, 1699; ¹H NMR (300 MHz; 60 °C; CDCl₃) δ 1.08 and 1.01 (d, *J* 6.6 and 7.0 Hz, respectively; 3H), 1.24-1.43 (m, 1H), 1.43-1.62 (m, 4H), 1.68-1.80 (m, 1H), 2.95 and 2.69 (br t, *J* 13.0 and 12.6 Hz, respectively; 1H), 3.67 and 3.63 (dd, *J* 5.9 and 9.0 Hz, 1H), 3.81 and 3.84 (dd, *J* 8.1/11.0 and 7.3/11.0 Hz, respectively; 1H), 3.88-4.01 (m, 1H), 4.05-4.15 (m, 1H), 4.20 and 4.30-4.40 (dt and m, *J* 6.0 and 8.9 Hz, 1H), 4.29 (t, br, *J* 8.0 Hz, 1H), 4.47-4.58 and 4.61-4.70 (m, 1H), 5.00/5.06 and 5.08 (d/d and s, respectively, *J* 12.5 Hz, 2H), 7.10-7.50 (m, 5H); ¹³C NMR (75.5 MHz; 60 °C; CDCl₃) δ 15.1 and 14.7, 19.1 and 19.3, 25.3 and 25.2, 25.7 and 27.5, 36.0 and 36.5, 40.2 and 39.7, 42.9 and 42.8, 54.6 and 52.9, 61.8 and 61.7, 67.1 and 67.0, 127.9 and 127.8, 128.0, 128.4 and 128.5, 137.4 and 137.3, 153.7 and 153.3, 155.6 and 156.0, 175.8 and 175.9; MS (EI): *m/z* 225 (7%), 218 (28%), 175 (7%), 174 (53%), 138 (7%), 92 (8%), 91 (10%), 65 (5%); HRMS (EI): found 360.1685; calc. for C₁₉H₂₄N₂O₅ [M]⁺ 360.1685.

(2*SR*, 1'*SR*) and (2*RS*, 1'*SR*) Methyl-2-[2'-(2-oxo-1,3-oxazolan-3-yl)-1'-methyl-2'-oxoethyl]-1-azolanecarboxylate (**29/30**)

Reaction temperatures T1 = T2 = -23 °C. The product was purified by chromatography on silica gel (impregnated with Et₃N, 50% ethyl acetate-hexane) to afford a 10:1 mixture of **29** and **30** (0.13 g, 50%; determined by GC analysis) as an oil. Found: C, 53.14; H, 6.52; N, 10.33.

Calc. for C₁₂H₁₈N₂O₅ C, 53.33; H, 6.71; N, 10.36%. IR $\nu_{\max}/\text{cm}^{-1}$ 1776, 1699; Data for **29**: ¹H NMR (300 MHz; 60 °C; CDCl₃) δ 1.12 (d, *J* 7.0 Hz, 3H), 1.73-1.87 (m, 1H), 1.87-2.05 (m, 3H), 3.24-3.37 (m, 1H), 3.37-3.51 (m, 1H), 3.63 (s, 3H), 3.91-4.02 (m, 2H), 4.02-4.10 (m, 1H), 4.14 (qt, *J* 6.9 Hz, 1H), 4.22-4.43 (m, 2H); ¹³C NMR (75.5 MHz; 60 °C; CDCl₃) δ 13.0, 23.4, 28.7, 39.9, 43.1, 46.9, 52.0, 60.2, 61.8, 153.4, 156.0, 175.5.

(2*SR*, 1'*SR*) and (2*RS*, 1'*SR*) Methyl-2-[2'-(2-oxo-1,3-oxazolan-3-yl)-1'-methyl-2'-oxoethyl]-1-piperidine-carboxylate (**31/32**)

Reaction temperatures T1=T2= -23 °C. The product was purified by chromatography on silica gel (impregnated with Et₃N, 50% ethyl acetate-hexane) to afford a 1.2:1 mixture of **31** and **32** (0.20 g, 70% determined by GC analysis) as a colorless solid. The isomers were separated by flash chromatography on silica gel (impregnated with Et₃N, 30% ethyl acetate-hexane). MS (EI): *m/z* 143 (9%), 142 (100%), 70 (12%), 42 (6%); HRMS (EI): found 284.1376; calc. for C₁₃H₂₀N₂O₅ [M]⁺ 284.1372. Data for **31**: mp 104.1-104.8 °C; IR $\nu_{\max}/\text{cm}^{-1}$ 1774, 1701; ¹H NMR (300 MHz; 50 °C; CDCl₃) δ 1.16 (d, *J* 6.3 Hz, 3H), 1.30-1.50 (m, 1H), 1.50-1.70 (m, 4H), 1.70-1.90 (m, 1H), 2.98 (dt, *J* 11.1 and 3.0 Hz, 1H), 3.67 (s, 3H), 3.90-4.07 (m, 3H), 4.28-4.42 (m, 2H), 4.50-4.65 (m, 2H); ¹³C NMR (75.5 MHz; 50 °C; CDCl₃) δ 15.3, 19.1, 25.3, 25.6, 35.9, 40.1, 43.0, 52.5, 54.3, 61.9, 153.5, 156.1, 175.6. Data for **32**: IR $\nu_{\max}/\text{cm}^{-1}$ 1774, 1741, 1701; ¹H NMR (300 MHz; 50 °C; CDCl₃) δ 1.10 (d, *J* 6.8 Hz, 3H), 1.30-1.50 (m, 2H), 1.50-1.70 (m, 4H), 2.74 (t, *J* 12.6 Hz, 1H), 3.70 (s, 3H), 4.03 (t, *J* 8.1 Hz, 2H), 4.05-4.15 (m, 1H), 4.41 (t, *J* 8.1 Hz, 2H), 4.35-4.50 (m, 1H), 4.60-4.72 (m, 1H); ¹³C NMR (75.5 MHz; 50 °C; CDCl₃) δ 14.7, 19.4, 25.2, 27.5, 36.3, 39.6, 42.8, 52.4, 52.7, 61.8, 153.1, 156.5, 175.7.

(2*S*, 1'*S*) and (2*R*, 1'*S*) Benzyl 2-{2'-[(4*R*)-4-benzyl-2-oxo-1,3-oxazolan-3-yl]-1'-methyl-2'-oxoethyl}-1-azolanecarboxylate (**33/34**)

Reaction temperatures T1= 0°C, T2= -23 °C. The product was purified by chromatography on silica gel (impregnated with Et₃N, 20% ethyl acetate-hexane) to afford a 5:1 mixture of **33** and **34** (0.25 g, 57%; determined by GC and ¹H NMR analysis) as an oil. MS (EI): *m/z* 204 (5%), 160 (17%), 149 (15%), 124 (15%), 92 (7%), 91 (100%), 65 (7%); HRMS (EI): found 301.1553; calc. for C₁₇H₂₁N₂O₃ [M-Cbz]⁺ 301.1552. Data for **33**: IR $\nu_{\max}/\text{cm}^{-1}$ 1785, 1709; ¹H NMR (300 MHz; 60 °C; CDCl₃) δ 1.14 (d, *J* 6.6 Hz, 3H), 1.76-1.90 (m, 1H), 1.90-2.10 (m, 3H), 2.43

(br t, J 13.3 Hz, 1H), 3.29-3.50 (m, 2H), 3.50-3.70 (m, 1H), 4.02 (dd, J 3.5 and 9.0 Hz, 1H), 4.11 (dd, J 3.0 and 7.2 Hz, 1H), 4.20-4.35 (m, 2H), 4.57-4.65 (m, 1H), 5.08 (d, J 12.6 Hz, 1H), 5.15 (d, J 12.6 Hz, 1H), 7.10-7.40 (m, 10H); ^{13}C NMR (75.5 MHz; 50 °C; CDCl_3) δ 13.1, 23.7, 28.4, 38.0, 40.5, 47.1, 55.5, 59.9, 66.1, 66.7, 127.1, 127.7, 128.3, 128.8, 128.9, 129.3, 136.0, 137.2, 153.1, 155.1, 175.1. Data for **34**: ^1H NMR (300 MHz; 50 °C; CDCl_3) δ 1.19 (d, J 7.0 Hz, 3H), 1.76-1.90 (m, 1H), 1.90-2.10 (m, 3H), 2.61 (dd, J 11.0 and 10.2 Hz, 1H), 3.29-3.50 (m, 2H), 3.50-3.70 (m, 1H), 4.02 (dd, J 3.5 and 9.0 Hz, 1H), 4.11 (dd, J 3.0 and 7.2 Hz, 1H), 4.20-4.35 (m, 1H), 4.35-4.46 (m, 1H), 4.60-4.70 (m, 1H), 5.09 (d, J 12.6 Hz, 1H), 5.12 (d, J 12.6 Hz, 1H), 7.10-7.40 (m, 10H); ^{13}C NMR (75.5 MHz; 50 °C; CDCl_3) δ 13.8, 23.7, 29.9, 38.2, 40.5, 46.9, 55.6, 59.7, 66.2, 66.9, 127.2, 127.8, 128.3, 128.8, 128.9, 129.3, 136.0, 137.2, 153.2, 155.7, 175.5.

(2*S*, 1'*S*) and (2*R*, 1'*S*) Benzyl 2- {2'- [(4*R*)- 4- benzyl- 2-oxo- 1,3- oxazolan- 3- yl]- 1'- methyl- 2'- oxoethyl]- hexahydro-1- pyridinecarboxylate (**35/36**)

Reaction temperatures T1 = T2 = 0 °C. The product was purified by chromatography on silica gel (impregnated with Et_3N , 20% ethyl acetate-hexane) to afford a 1.8:1 mixture of **35** and **36** (0.23 g, 50%; determined HPLC and ^1H NMR analysis) as an oil. The isomers were separated by flash chromatography on silica gel (impregnated with Et_3N , 15% ethyl acetate-hexane). MS (EI): m/z 315 (11%), 218 (36%), 175 (8%), 174 (61%), 138 (8%), 92 (8%), 91 (100%), 55 (5%); HRMS (EI): found 450.2152; calc. for $\text{C}_{26}\text{H}_{30}\text{N}_2\text{O}_5$ $[\text{M}]^+$ 450.2155. Data for **35**: colorless solid; mp 123.2-123.9 °C; $[\alpha]_D^{20}$ -163.48 (c 1.3, CH_2Cl_2); IR $\nu_{\text{max}}/\text{cm}^{-1}$ 1776, 1770; ^1H NMR (300 MHz; 50 °C; CDCl_3) δ 1.19 (d, J 6.2 Hz, 3H), 1.34-1.52 (m, 1H), 1.54-1.70 (br d, J 5.5 Hz, 4H), 1.74-1.90 (br d, J 6.2 Hz, 1H), 2.50 (dd, J 8.2 and 11.2 Hz, 1H), 3.08-3.20 (m, 1H), 3.14 (d, J 2.8 and 13.4 Hz, 1H), 4.02-4.22 (m, 3H), 4.59-4.78 (m, 3H), 5.05 (d, J 12.8 Hz, 1H), 5.11 (d, J 12.5 Hz, 1H), 7.00-7.50 (m, 10H); ^{13}C NMR (75.5 MHz; 50 °C; CDCl_3) δ 15.2, 19.0, 25.4, 25.6, 36.0, 37.8, 40.2, 54.7, 55.3, 65.9, 67.1, 127.4, 127.9, 128.0, 128.5, 129.0, 129.6, 135.7, 137.3, 153.8, 155.6, 175.9; Data for **36**: colorless oil; $[\alpha]_D^{20}$ -70.42 (c 1.7, CH_2Cl_2); ^1H NMR (300 MHz; 50 °C; CDCl_3) δ 1.09 (d, J 6.2 Hz, 3H), 1.38-1.80 (m, 6H), 2.73 (dd, J 9.5 and 13.2 Hz, 1H), 2.70-2.86 (br m, 1H), 3.31 (dd, J 3.3 and 13.2 Hz, 1H), 4.04-4.28 (m, 3H), 4.43-4.58 (m, 1H), 4.65-4.86 (m, 2H), 5.17 (s, 2H), 7.10-7.60 (m, 10H); ^{13}C NMR (75.5 MHz; 50 °C; CDCl_3) δ 14.8, 19.2, 25.2, 27.6, 36.3, 38.1, 39.6, 53.1, 55.4, 66.0, 67.1, 127.6, 128.0, 128.1, 128.6, 129.2, 129.5, 135.5, 137.3, 153.4, 156.2, 176.0.

(2*S*, 1'*S*) and (2*R*, 1'*S*) Methyl 2- {2'- [(4*R*)- 4- benzyl- 2-oxo-1,3-oxazolan- 3- yl]- 1'- methyl- 2'- oxoethyl]- 1-azolane-carboxylate (**37/38**)

Reaction temperatures T1 = 0 °C, T2 = -23 °C. The product was purified by chromatography on silica gel (impregnated with Et_3N , 20% ethyl acetate-hexane) to afford a 6:1 mixture of **37** and **38** (0.18 g, 50%; determined by HPLC and ^1H NMR analysis) as an oil. IR $\nu_{\text{max}}/\text{cm}^{-1}$ 1783, 1700; ^1H NMR (300 MHz; 55 °C; CDCl_3) δ 1.16 and 1.21 (d, J 6.5 and 7.0 Hz, respectively; 3H) 1.77-1.90 (m, 1H), 1.90- 2.10 (m, 3H), 2.60 and 2.72 (dd, J 10.4/13.3 and 9.2/12.3 Hz, respectively; 1H), 3.30-3.50 (m, 2H), 3.50-3.62 (m, 1H), 3.68 and 3.70 (s, 3H), 4.08-4.22 (m, 2H), 4.22- 4.40 (m, 2H), 4.62-4.75 (m, 1H), 7.10-7.40 (m, 5H); ^{13}C NMR (75.5 MHz; 55 °C; CDCl_3) δ 12.9, 23.8, 28.3, 38.1, 40.4, 47.2 and 47.0, 52.2 and 52.1, 55.6 and 55.5, 59.7 and 59.8, 66.1 and 66.2, 127.2, 129.0, 129.3, 135.9, 153.1, 155.9, 175.2; MS (EI): m/z 155 (9%), 129 (7%), 128 (100%); HRMS (EI): found 184.0974; calc. for $\text{C}_9\text{H}_{14}\text{NO}_3$ $[\text{M}-\text{C}_{10}\text{H}_{10}\text{NO}_2]^+$ 184.0974.

(2*S*, 1'*S*) and (2*R*, 1'*S*) Methyl 2- {2'- [(4*R*)- 4- benzyl- 2-oxo-1,3-oxazolan- 3- yl]- 1'- methyl- 2'- oxoethyl]- hexahydro-1-pyridinecarboxylate (**39/40**)

Reaction temperatures T1 = 0 °C, T2 = -23 °C. The product was purified by chromatography on silica gel (impregnated with Et_3N , 20% ethyl acetate-hexane) to afford a 1.9:1 mixture of **39** and **40** (0.23 g, 61%; determined by GC and ^1H NMR analysis) as an oil. IR $\nu_{\text{max}}/\text{cm}^{-1}$ 1777, 1694; ^1H NMR (300 MHz; 50 °C; CDCl_3) δ 1.18 and 1.11 (d, J 6.6 Hz, 3H), 1.32-1.84 (m, 6H), 2.60 and 2.74 (dd, J 9.5/13.6 and 9.7/13.4 Hz, respectively; 1H), 3.09 and 2.70-2.80 (dt and m, J 2.6 and 13.7 Hz, 1H), 3.21 and 3.32 (dd, J 3.3/13.6 and 3.3/ 13.4, respectively; 1H), 3.64 and 3.72 (s, 3H), 4.00-4.20 (m, 3H), 4.60-4.78 (m, 2H), 4.60-4.78 and 4.42-4.58 (m, 1H), 7.14-7.36 (m, 5H); ^{13}C NMR (75.5 MHz; 50 °C; CDCl_3) δ 15.2 and 14.6, 19.0 and 19.2, 25.3 and 25.1, 25.5 and 27.5, 36.0 and 36.3, 37.8 and 38.1, 40.1 and 39.5, 52.4 and 52.3, 54.7 and 53.0, 55.3 and 55.4, 66.0 and 66.1, 127.5 and 127.6, 129.1 and 129.2, 129.5, 135.7 and 135.5, 153.8, 156.3, 176.1; MS (EI): m/z 143 (7%), 142 (100%); HRMS (EI): found 315.1709; calc. for $\text{C}_{18}\text{H}_{23}\text{N}_2\text{O}_3$ $[\text{M}-\text{CO}_2\text{Me}]^+$ 315.1709.

(2*R*, 1'*R*) tert-Butyl 2- {2'- [(4*S*)- 4- benzyl- 2- oxo- 1,3-oxazolan- 3- yl]- 1'- phenyl-2'- oxoethyl]- 1- azolane-carboxylate (**52**)

Reaction temperatures T1 = 0 °C, T2 = -23 °C. The

product was purified by flash chromatography on silica gel (20% ethyl acetate-hexane) to yield the single isomer **52** (0.33 g, 70%) as a colorless oil. $[\alpha]_D^{20} +165.8$ (*c* 3.2, CH₂Cl₂); IR $\nu_{\max}/\text{cm}^{-1}$ 1778, 1693; ¹H NMR (300 MHz; 60 °C; CDCl₃) δ 1.51 (s, 9H), 1.40-1.70 (m, 1H), 1.70-1.95 (m, 3H), 2.74 (dd, *J* 9.9 and 13.6 Hz, 1H), 3.03-3.22 (br m, 1H), 3.35 (dt, *J* 10.7 and 7.8 Hz, 1H), 3.50 (br d, *J* 12.1 Hz, 1H), 3.98 (t, *J* 8.8 Hz, 1H), 4.05 (dd, *J* 2.6 and 8.8 Hz, 1H), 4.52-4.72 (br m, 2H), 5.53 (br d, *J* 5.9 Hz, 1H) 7.20-7.40 (m, 10H); ¹³C NMR (75.5 MHz; 60 °C; CDCl₃) δ 23.1, 28.6, 28.9, 38.0, 46.6, 51.8, 55.9, 59.6, 65.8, 79.6, 127.2, 127.5, 128.5, 128.9, 129.5, 129.7, 136.0, 136.1, 152.7, 154.7, 172.8; MS (EI): *m/z* 295 (9%), 170 (22%), 118 (39%), 114 (72%), 113 (7%), 91 (25%), 90 (7%), 70 (75%), 69 (9%), 68 (13%), 57 (100%); HRMS (EI): found 391.1655; calc. for C₂₃H₂₃N₂O₄ [M-OC₄H₉]⁺ 391.1658.

(2*R*, 1'*R*) and (2*S*, 1'*R*) Benzyl 2- {2'- [(4*S*)- 4- benzyl- 2- oxo- 1,3-oxazolan-3-yl]- 1'- phenyl- 2'- oxoethyl} – hexahydro-1-pyridinecarboxylate (**54/55**)

Reaction temperatures T1 = T2 = 0 °C. The product was purified by flash chromatography on silica gel (20% ethyl acetate-hexane) to afford a 12:1 mixture of **54** and **55** (0.31 g, 60%; determined by ¹H NMR and HPLC analysis) as a colorless solid. Mp 56.2-56.9°C; IR $\nu_{\max}/\text{cm}^{-1}$ 1774, 1697; MS (EI): *m/z* 174 (5%), 118 (14%), 97 (7%), 95 (9%), 91 (70%), 85 (9%), 83 (30%), 81 (27%), 73 (5%), 71 (10%), 69 (63%), 68 (9%), 67 (12%), 65 (5%), 58 (100%), 57 (29%), 56 (7%), 55 (32%); HRMS (EI): found 377.1819; calc. for C₂₃H₂₅N₂O₃ [M-Cbz]⁺ 377.1865. Data for **54**: ¹H NMR (300 MHz; 55 °C; CDCl₃) δ 1.24-1.82 (m, 6H), 2.67 (dd, *J* 9.3 and 13.4 Hz, 1H), 3.14 (dd, *J* 2.9 and 13.4 Hz, 1H), 3.12-3.32 (m, 1H), 3.96-4.14 (m, 2H), 4.14-4.32 (m, 1H), 4.52-4.66 (m, 1H), 5.17 (br s, 2H), 5.24-5.36 (m, 1H), 6.03 (d, *J* 11.4 Hz, 1H), 7.01-7.20 (d, *J* 11.4 Hz, 2H), 7.20-7.45 (m, 11H), 7.45-7.62 (d, *J* 6.9 Hz, 2H); ¹³C NMR (75.5 MHz; 55 °C; CDCl₃) δ 19.1, 25.5, 25.6, 37.9, 40.3, 47.3, 54.9, 55.5, 65.8, 67.3, 127.2, 127.8, 127.9, 128.0, 128.4, 128.8, 128.9, 129.4, 129.5, 135.3, 136.1, 137.1, 153.5, 155.5, 172.1.

(2*R*, 1'*R*) and (2*S*, 1'*R*) Methyl 2- {2'- [(4*S*)- 4- benzyl- 2- oxo- 1,3-oxazolan-3-yl]- 1'- phenyl- 2'- oxoethyl} – hexahydro-1-pyridinecarboxylate (**56/57**)

Reaction temperatures T1= 0 °C, T2= -23 °C. The product was purified by flash chromatography on silica gel (20% ethyl acetate-hexane) to afford a 8:1 mixture of **56** and **57** (0.32 g, 73%; determined by GC and ¹H NMR analysis) as a colorless solid. The major isomer **56** was

separated by recrystallization (ethyl acetate-hexane). Data for **56**: mp 175.1-175.8 °C; $[\alpha]_D^{20} +87.9$ (*c* 2.0, CH₂Cl₂); IR $\nu_{\max}/\text{cm}^{-1}$ 1783, 1700; ¹H NMR (300 MHz; 50 °C; CDCl₃) δ 1.20-1.30 (m, 1H), 1.35-1.60 (m, 3H), 1.60-1.80 (m, 2H), 2.75 (dd, *J* 9.2 and 13.6, CH₂-3, 1H), 3.18 (dd, *J* 2.9 and 13.2 Hz, 1H), 3.12-3.27 (m, 1H), 3.73 (s, 3H), 4.01-4.24 (m, 2H), 4.10-4.24 (m, 1H), 4.54-4.66 (m, 1H), 5.10-5.30 (m, 1H), 6.01 (d, *J* 11.4 Hz, 1H), 7.16 (d, *J* 6.6 Hz, 2H), 7.20-7.42 (m, 6H), 7.55 (d, *J* 6.6 Hz, 2H). ¹³C NMR (75.5 MHz; 50 °C; CDCl₃) δ 19.0, 25.4, 25.5, 37.9, 40.1, 47.2, 52.7, 54.8, 55.5, 65.8, 127.4, 128.0, 129.0, 129.1, 129.5, 129.5, 135.4, 136.2, 153.7, 156.3, 172.4; MS (EI): *m/z* 143 (5%), 142 (100), 118 (5), 91 (5); HRMS (EI): found 436.1999; calc. for C₂₅H₂₈N₂O₅ [M]⁺ 436.1998.

(2*R*, 1'*R*) tert-Butyl 2- {2'- [(4*S*)- 4- benzyl- 2- oxo- 1,3-oxazolan- 3- yl]- 1'- chloropropyl- 2'- oxoethyl}- 1-azolanecarboxylate (**58**)

Reaction temperatures T1=T2= -23 °C. The product was purified by flash chromatography on silica gel (15% ethyl acetate-hexane) to yield the single isomer **58** (0.38 g, 81%) as a colorless oil. $[\alpha]_D^{20} +49.6$ (*c* 3.6, CH₂Cl₂); IR $\nu_{\max}/\text{cm}^{-1}$ 1780, 1689; ¹H NMR (500 MHz; 50 °C; CDCl₃) δ 1.44 (s, 9H), 1.50-2.20 (m, 8H), 2.60 (dd, *J* 13.3 and 10.4 Hz, 1H), 3.27 (m, 1H), 3.40-3.65 (m, 2H), 3.50 (t, *J* 6.40 Hz, 2H), 4.12 (m, 2H), 4.20-4.35 (br s, 2H), 4.68 (m, 1H), 7.29 (m, 5H); ¹³C NMR (125 MHz; 50 °C; CDCl₃) δ 21.6, 23.6, 28.5, 28.7, 30.7, 38.2, 44.5, 45.7, 47.1, 55.6, 58.7, 66.1, 79.8, 127.2, 128.9, 129.3, 135.7, 153.1, 154.9, 174.0; MS (EI): *m/z* 295 (10%), 204 (10%), 188 (6%), 186 (17%), 182 (7%), 181 (6%), 178 (6%), 170 (17%), 134 (6%), 121 (15%), 119 (45%), 118 (6%), 117 (16%), 116 (7%), 115 (10%), 114 (74%), 96 (7%), 92 (12%), 91 (50%), 86 (9%), 70 (100%), 68 (9%), 65 (10%), 57 (83%), 55 (25), 53 (6%); HRMS (EI): found 363.1475; calc. for C₁₉H₂₄N₂O₃Cl [M-Boc]⁺ 363.1475.

(2*R*, 1'*R*) Benzyl 2- {2'- [(4*S*)- 4- benzyl- 2- oxo- 1,3-oxazolan- 3- yl]- 1'- chloropropyl-2'- oxoethyl}- 1-azolanecarboxylate (**60**)

Reaction temperatures T1=T2= -23 °C. The product was purified by flash chromatography on silica gel (20% ethyl acetate-hexane) to yield **60** (0.36 g, 73%) as a colorless oil and a single isomer. $[\alpha]_D^{20} +30.4$ (1,1, CH₂Cl₂); IR $\nu_{\max}/\text{cm}^{-1}$ 1778, 1693; ¹H NMR (300 MHz; 55 °C; CDCl₃) δ 1.58-2.12 (m, 8H); 2.40 (1H, br t, *J* 10.8, CHHPh); 3.34-3.52 (m, 2H); 3.45 (t, *J* 6.40 Hz, 2H); 3.52-3.69 (m, 1H); 4.04 (dd, *J*=3.5 and 8.9 Hz, 1H); 4.10 (t, *J* 8,1 Hz, 1H) 4.24-4.40 (br m, 2H); 4.59-4.71 (m, *J* 3.4 and 14.3, 1H);

5.08 (d, *J* 12.8 Hz, 1H); 5.13 (d, *J* 12.3 Hz, 1H); 7.10-7.20 (m, 1H); 7.20-7.60 (m, 9H); ¹³C NMR (125 MHz; 50 °C; CDCl₃) δ 23.6; 25.8; 28.8; 30.7; 38.0; 44.5; 45.7; 47.2; 55.6; 59.6; 66.1; 66.8; 127.2; 127.8; 128.4; 128.8; 128.9; 129.3; 135.8; 137.1; 153.2; 155.2; 173.9; MS (EI): *m/z* 204 (25%), 186 (11%), 160 (39%), 92 (6%), 91 (100%), 70 (5%); HRMS (EI): found 363.1476 C₁₉H₂₄N₂O₃Cl [M-Cbz]⁺ 363.1475.

(2*R*, 1'*R*) and (2*S*, 1'*R*) Benzyl 2- {2'- [(4*S*)- 4- benzyl- 2-oxo- 1,3-oxazolan-3-yl]- 1'- chloropropyl- 2'- oxoethyl} – hexahydro- 1- pyridinecarboxylate (**62/63**)

Reaction temperatures T1 = T2 = -23 °C. The product was purified by flash chromatography on silica gel (20% ethyl acetate-hexane) to afford a 4:1 mixture of **62** and **63** (0.31 g, 60%; determined by ¹H NMR and HPLC analysis) as a colorless solid. mp 86.5-87.3 °C; MS (EI): *m/z* 219 (7%), 218 (63%), 175 (11%), 174 (74%), 92 (8%), 91 (100%), 84 (5%); HRMS (EI): found 377.1632; calc. for C₂₀H₂₆N₂O₃Cl [M-Cbz]⁺ 377.1632. The isomers were separated by flash chromatography on silica gel (15% ethyl acetate-hexane). Data for **62**: [α]_D²⁰ +89.7 (1.1, CH₂Cl₂); IR ν_{max}/cm⁻¹ 1772, 1699; ¹H NMR (300 MHz; 55 °C; CDCl₃) δ 1.28-1.94 (m, 10H), 2.42 (dd, *J* 10.3 and 13.3 Hz, 1H), 3.11 (t, *J* 12.5 Hz, 1H), 3.18 (dd, *J* 3.1 and 13.4 Hz, 1H), 3.46-3.60 (m, 2H), 4.00-4.20 (m, 3H), 4.60-4.82 (m, 3H), 5.03 (d, *J* 12.9 Hz, 1H), 5.08 (d, *J* 5.1 Hz, 1H), 7.09 (d, *J* 6.6 Hz, 2H), 7.10-7.40 (m, 8H); ¹³C NMR (75.5 MHz; 55 °C; CDCl₃) δ 19.3, 25.5, 26.2, 28.0, 29.8, 37.9, 40.4, 40.9, 44.4, 54.5, 55.4, 66.0, 67.2, 127.2, 127.8, 128.4, 128.9, 129.3, 135.5, 136.9, 153.6, 155.2, 174.7. Data for **63**: [α]_D²⁰ +48.0 (1.1, CH₂Cl₂); IR ν_{max}/cm⁻¹ 1778, 1699; ¹H NMR (300 MHz; 55 °C; CDCl₃) δ 1.33-1.78 (br m, 10H), 2.65 (dd, *J* 9.9 and 13.2 Hz, 1H), 2.78 (br t, *J* 12.3 Hz, 1H), 3.27-3.40 (m, 3H), 4.00-4.20 (m, 3H), 4.58-4.77 (m, 3H), 5.11 (br d, *J* 13.0 Hz, 1H), 5.17 (br d, *J* 13.0 Hz, 1H), 7.10-7.40 (m, 10H); ¹³C NMR (75.5 MHz; 55 °C; CDCl₃) δ 19.4, 25.3, 27.5, 27.8, 29.6, 38.2, 39.9, 40.9, 44.4, 53.1, 55.6, 66.1, 67.3, 127.5, 128.0, 128.5, 129.0, 129.3, 135.2, 137.1, 153.3, 155.7, 174.8.

(2*S*, 2'*S*)- 2- (1'- tert-butoxycarbonyl- azolan- 2'- yl) propanoic acid [(*-*)-**41**]

To a solution of **11** (0.23 g, 0.57 mmol) in THF (3.2 cm³) at 0 °C was added water (0.81 cm³), 30% aq. H₂O₂ soln. (0.23 cm³), and a soln. of LiOH. H₂O (0.040 g, 0.95 mmol) in water (1.2 cm³). The mixture was stirred 5 h at 0°C and a solution of Na₂SO₃ (0.29 g, 2.3 mmol) in water (1.7 cm³) was added. The mixture was let to stir 16 h at rt,

the solvent was evaporated under reduced pressure and the aqueous layer was extracted with CH₂Cl₂ (3 x 5 cm³). The combined CH₂Cl₂ extracts were dried over MgSO₄, filtered and the solvent was removed under reduced pressure. Recrystallization (Et₂O:Hexane) yielded (*R*)-4-benzyl-2-oxazolidinone (0.092 g, 95%). The aqueous layer was acidified to pH 2.0 with aq. 1M HCl and extracted with ethyl acetate (3 x 5 cm³). The combined ethyl acetate extracts were dried over MgSO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by chromatography on silica gel (10 % ethyl acetate:hexane) to afford the acid (*-*)-**41** (0.13 g, 91%) as a white solid: mp 104.6-105.7 °C; [α]_D²⁰-31.0 (*c* 4.1, CH₂Cl₂); ¹H NMR (300 MHz; 50 °C; CDCl₃) δ 1.06 (d, *J* 7.3 Hz, 3H), 1.46 (s, 9H), 1.70-1.90 (m, 3H), 1.90-2.04 (m, 1H), 3.18-3.38 (m, 2H), 3.44-3.62 (m, 1H), 4.14-4.28 (m, 1H), 7.30-7.80 (m, 1H); ¹³C NMR (75.5 MHz; 50 °C; CDCl₃) δ 9.9, 23.7, 27.1, 28.3, 41.4, 47.2, 58.3, 79.8, 155.0, 179.6. Found: C, 59.28; H, 8.83; N, 5.61. Calc. for C₁₂H₂₁NO₄ C, 59.24; H, 8.70; N, 5.76%.

(2*S*, 2'*S*) 2- (1'- Benzyloxycarbonyl- hexahydro- 2'- pyridinyl) propanoic acid (**42**)

The same procedure described above for the preparation of (*-*)-**5** was employed for a 1.8:1 mixture of **27:28** (0.23 g, 0.57 mmol). Recrystallization (Et₂O:Hexane) of the solid residue from the CH₂Cl₂ extract yielded (*R*)-4-benzyl-2-oxazolidinone (0.092 g, 95%). The residue isolated from the ethyl acetate extract was purified by chromatography on silica gel (15% ethyl acetate/hexane) to afford a 1.8:1 mixture of **42** and the C-2'epimer (0.13 g, 91%) as a colorless oil. IR ν_{max}/cm⁻¹ 3162 (br), 1735, 1700; ¹H NMR (300 MHz; CDCl₃) δ 1.17 and 1.10 (d, *J* 6.8 Hz, 3H), 1.36-1.80 (m, 6H), 2.94-3.10 and 2.68 (m and t, br, respectively, *J* 12.5 Hz; 2H), 4.05-4.20 (m, 1H), 4.43 and 4.50 (br d, *J* 9.0 and 10.5 Hz, respectively; 1H), 5.09 and 5.13/5.17 (s and d/d, respectively, *J* 12.7 and 12.4 Hz; 2H), 7.20-7.40 (m, 5H), 8.00-8.10 (br m, 1H); ¹³C NMR (75.5 MHz; CDCl₃) δ 14.4 and 14.2, 18.6 and 18.9, 25.0 and 25.4, 27.3, 38.3 and 38.9, 39.7 and 39.4, 53.8 and 52.6, 67.2 and 67.1, 127.9, 127.9 and 128.0, 128.5, 136.9, 155.9 and 155.7, 180.8 and 179.8; MS (EI): *m/z* 91 (100%); HRMS (EI): found 156.1023; calc. for C₈H₁₄NO₂ [M-Cbz]⁺ 156.1025.

(2*SR*, 1'*SR*)- 2- [2'- (2- oxo- 1,3- oxazolan- 3- yl)-1'- methyl- 2'-oxoethyl]-1-pyrrolidine (**43**)

Procedure A: To a stirred solution of **7** (0.050 g, 0.16 mmol) in CH₂Cl₂ (4.0 cm³) at 0 °C was added CF₃CO₂H (0.12 cm³, 1.6 mmol) dropwise. The reaction was followed

by TLC analyses and quenched by the addition of saturated NaHCO_3 solution. After extraction with CH_2Cl_2 , the organic layer was dried over anhydrous MgSO_4 , filtered and concentrated in vacuo. The crude residue was purified by chromatography on silica gel (5% methanol:chloroform) to provide **43** (0.017 g, 50%) as a colorless solid.

Procedure B: To solution of **25** (0.045 g, 0.13 mmol) in MeOH (2.0 cm^3) was added 10% Pd-C (0.02 g). The resulting suspension was stirred at ambient temperature for 12 hr under hydrogen (1 atm). The reaction mixture was filtered through Celite, and the solvent was removed under reduced pressure. The residue was purified by chromatography on silica gel (5% methanol/chloroform/a few drops of NH_4OH) to afford **43** (0.021 g, 74%) as a white solid mp: 75.0-75.8 °C; ^1H NMR (300 MHz; CDCl_3) δ 1.22 (d, J 6.6 Hz, 3H), 1.45-1.55 (m, 1H), 1.76-1.95 (m, 1H), 2.01-2.12 (m, 1H), 2.24-2.39 (m, 2H), 3.20-3.31 (m, 1H), 3.37 (ddd, J 5.7, 10.1 and 12.5 Hz, 1H), 3.50 (dt, J 7.5 and 10.4 Hz, 1H), 3.58-3.87 (m, 3H), 4.12 (ddd, J 3.7, 5.1 and 13.8 Hz, 2H); ^{13}C NMR (75.5 MHz; CDCl_3) δ 11.4, 22.7, 32.6, 42.0, 43.5, 45.9, 57.9, 61.8, 153.0, 172.9.

(2*S*, 2'*R*)- 2- (1'- tert-butoxycarbonyl- azolan- 2'- yl) propanoic acid (+)-**44**

The same procedure described above for the preparation of (-)-**41** was employed for (+)-**12** (0.23 g, 0.57 mmol). Recrystallization (Et_2O :Hexane) yielded (R)-4-benzyl-2-oxazolidinone (0.092 g, 95%). The ethyl acetate extract was purified by chromatography on silica gel (10% ethyl acetate/hexane) to afford the acid (+)-**44** (0.13 g, 91%) as a white solid: mp 100.5-102.0 °C; IR $\nu_{\text{max}}/\text{cm}^{-1}$ 3483 (br), 3174 (br), 1732, 1697; $[\alpha]_{\text{D}}^{20}$ +71.1 (c 3.2 in CH_2Cl_2); ^1H NMR (300 MHz; 50 °C; CDCl_3) δ 1.16 (d, J 7.3 Hz, 3H), 1.46 (s, 9H), 1.70-2.06 (m, 4H), 2.94 (qt, J 6.6 Hz, 1H), 3.18-3.32 (m, 1H), 3.42-3.58 (m, 1H), 3.99-4.10 (m, 1H), 8.20-8.90 (m, 1H); ^{13}C NMR (75.5 MHz; 50 °C; CDCl_3) δ 13.7, 23.2, 28.3, 28.7, 42.6, 46.7, 59.5, 79.9, 155.5, 179.9. Found: C, 59.28; H, 8.83; N, 5.61. Calc. for $\text{C}_{12}\text{H}_{21}\text{NO}_4$, C, 59.24; H, 8.70; N, 5.76%.

(2*S*, 1'*R*) tert-Butyl- 2- [2'-[(4*R*)- 4- benzyl- 2- oxo-1,3-oxazolan- 3- yl]- 1'- methyl- 2'- oxoethyl]- 1- azolane-carboxylate [(-)-**45**]

To a solution of diisopropylamine (0.073 cm^3 , 0.52 mmol) in THF (1.0 cm^3) at -78 °C was added a 1.96 M solution of n-BuLi (0.27 cm^3 , 0.52 mmol) in hexane and the mixture was stirred 30 min. at -78 °C. A solution of **11** (0.20 g, 0.50 mmol) in THF (1.0 cm^3) was added dropwise,

and the solution was stirred 1 hr at -78 °C when it was quenched with satd. aq. NH_4Cl (2.0 cm^3). The layers were separated and the aqueous layer was extracted with CH_2Cl_2 (2 x 3 cm^3), and the combined organic layers were dried over MgSO_4 . After filtration, the solvent was removed under reduced pressure and the residue was purified by flash chromatography on silica gel to afford **11** (0.081 g, 38%) eluted with 15% ethyl acetate/hexane, (-)-**45** (0.081 g, 38%) eluted with 12% ethyl acetate/hexane, and N-acyl urea **46** (0.050 g, 20%; eluted with 30% ethyl acetate/hexane). Data for (-)-**45**: $[\alpha]_{\text{D}}^{20}$ -94.8 (c 1.4 in CH_2Cl_2); ^1H NMR (300 MHz; 55 °C; CDCl_3) δ 1.23 (d, J 7.0 Hz, 3H), 1.45 (s, 9H), 1.72-2.50 (m, 4H), 2.78 (dd, J 9.5 and 13.2 Hz, 1H), 3.16-3.38 (m, 1H), 3.36-3.60 (br s, 1H), 3.38-3.64 (br m, 1H), 3.90-4.08 (br m, 1H), 4.13-4.20 (m, 2H), 4.22-4.40 (br s, 1H), 4.58-4.70 (m, 1H), 7.19-7.35 (m, 5H); ^{13}C NMR (75.5 MHz; 55 °C; CDCl_3) δ 13.9, 23.6, 28.4, 29.5, 38.0, 41.8, 47.0, 55.7, 59.1, 66.2, 79.4, 127.2, 128.9, 129.4, 135.6, 153.3, 155.2, 175.4. Data for **46**: $[\alpha]_{\text{D}}^{20}$ +10.5 (c 2.4 in CH_2Cl_2); IR $\nu_{\text{max}}/\text{cm}^{-1}$ 3325 (br), 1693; ^1H NMR (300 MHz; 55 °C; CDCl_3) δ 0.94 (br d, J 6.9 Hz, 3H), 1.22 (br d, J 6.4 Hz, 12H), 1.75 (s, 9H), 1.56-1.88 (m, 4H), 2.84 (br d, J 6.9 Hz, 2H), 2.90-3.10 (br s, 1H), 3.14-3.28 (br m, 1H), 3.36-3.58 (br s, 1H), 3.78-4.00 (br m, 3H), 4.11 (br d, J 5.4 Hz, 2H), 4.34-4.52 (m, 1H), 6.00-6.14 (m, 1H), 7.12-7.30 (m, 5H); ^{13}C NMR (75.5 MHz; 55 °C; CDCl_3) δ 10.1, 21.0, 24.2, 26.4, 28.6, 38.0, 42.7, 46.2, 47.4, 50.3, 59.4, 65.4, 79.4, 126.5, 128.5, 129.3, 137.6, 154.7, 155.6, 173.6; MS (EI): m/z 403 (7%), 402 (19%), 365 (7%), 334 (7%), 257 (12%), 190 (12%), 189 (19%), 170 (27%), 137 (8%), 128 (40%), 124 (26%), 120 (7%), 117 (16%), 114 (42%), 98 (17%), 91 (17%), 86 (38%), 70 (100%), 57 (61%); HRMS (EI): found 503.3356; calc. for $\text{C}_{28}\text{H}_{45}\text{N}_3\text{O}_5$ $[\text{M}]^+$ 503.3359.

(2*S*, 2'*R*)- 2- (1'- tert-butoxycarbonyl- azolan- 2'- yl) propanoic acid [(-)-**44**]

The same procedure described above for the preparation of (-)-**11** was employed for (-)-**45** (0.23 g, 0.57 mmol). Recrystallization (Et_2O :Hexane) yielded (R)-4-benzyl-2-oxazolidinone (0.092 g, 95%). The residue isolated from the ethyl acetate extract was purified by chromatography on silica gel (10% ethyl acetate/hexane) to afford (-)-**44** (0.13 g, 91%) as a white solid, in yield. $[\alpha]_{\text{D}}^{20}$ -75.7 (c 2.4 in CH_2Cl_2).

(2*S*, 2'*S*)- 2- (1'- benzyloxycarbonyl- hexahydro- pyridin- 2'-yl)- 2-methylethanol (**47**)

To a solution of **35** (0.21 g, 0.46 mmol) in THF (3.42 cm^3) at 0 °C was added dropwise a solution of NaBH_4

(0.70g, 1.8 mmol) in H₂O (0.43 cm³). The mixture was stirred at room temperature for 16 hr, and quenched with a 2.0 N aqueous solution of HCl (1.24 cm³). The mixture was extracted with CH₂Cl₂, and the organic layer dried with MgSO₄. After filtration, the solvent was removed under reduced pressure and the residue was purified by chromatography on silica gel to afford **47** (0.089 g, 70%; 20% ethyl acetate/hexane) as a colorless oil and (R)-4-benzyl-2-oxazolidinone (0.067 g, 82%; 50% ethyl acetate/hexane). [α]_D²⁰ -31.1 (c 0.8 in CH₂Cl₂); IR ν_{\max} /cm⁻¹ 3460 (br), 1678; ¹H NMR (300 MHz; 50 °C; CDCl₃) δ 1.02 (d, *J* 6.9 Hz, 3H), 1.40-1.70 (m, 6H), 1.78-1.90 (br m, 1H), 1.94-2.10 (br s, 1H), 2.77 (dt, *J* 2.7 and 11.8 Hz, 1H), 3.30-3.48 (m, 2H), 4.08 (br d, *J* 11.8 Hz, 2H), 5.13 (d, *J* 12.4 Hz, 1H), 5.17 (d, *J* 12.4 Hz, 1H), 7.20-7.41 (m, 5H); ¹³C NMR (75.5 MHz; CDCl₃) δ 14.7, 18.7, 25.3, 25.7, 32.5, 39.8, 52.1, 64.1, 67.4, 127.9, 128.2, 128.6, 136.5, 156.9, MS (CI): *m/z* 280 (6%), 279 (42%), 278 (100%), 276 (9%), 260 (15%), 235 (26%), 234 (78%), 219 (7%), 218 (44%), 174 (17%), 171 (6%), 170 (49%), 144 (12%), 142 (6%), 92 (6%), 91 (43%), 84 (12%).

(2*S*, 2'*R*)- 2- (1'- benzyloxycarbonyl- hexahydro- pyridin- 2'-yl)- 2-methylethanol (**48**)

The same procedure described above for **47** was employed starting with **36** (0.21 g, 0.46 mmol). The residue was purified by chromatography on silica gel to afford **48** (0.09 g, 0.32 mmol, 70%; 30% ethyl acetate/hexane) as a colorless oil and (R)-4-benzyl-2-oxazolidinone (0.067 g, 82%; 50% ethyl acetate/hexane). [α]_D²⁰ +15.0 (c 1.7 in CH₂Cl₂); IR ν_{\max} /cm⁻¹ 3460 (br), 1678; ¹H NMR (300 MHz; 50 °C; CDCl₃) δ 0.90 (d, *J* 6.9 Hz, 3H), 1.40-1.70 (m, 5H), 1.70-1.90 (br m, 2H), 2.04-2.18 (m, 1H), 2.78 (dt, *J* 2.9 and 14.0 Hz, 1H), 3.49 (dd, *J* 5.8 and 11.0 Hz, 1H), 3.61 (dd, *J* 4.8 and 10.9 Hz, 1H), 4.04-4.20 (br m, 2H), 5.13 (s, 2H), 7.20-7.41 (m, 5H); ¹³C NMR (75.5 MHz; CDCl₃) δ 13.3, 19.1, 25.1, 26.4, 35.0, 39.8, 52.5, 65.6, 67.0, 127.8, 127.9, 128.5, 137.0, 156.2.

Benzyl (2*S*)- 2- isopropylhexahydro- 1- pyridinecarboxylate [(-)-**49**]

To a solution of **47** (0.053 g, 0.19 mmol) in CH₂Cl₂ (0.6 cm³) at 0 °C was added Et₃N (0.029 cm³, 0.21 mmol), catalytic amount of DMAP, and TsCl (0.040 g, 0.21 mmol). The mixture was stirred 1 h at 0 °C, the solvent removed under reduced pressure and the residue was purified by chromatography on silica gel (10% ethyl acetate/hexane) to afford the tosylate (0.060 g, 0.14 mmol) in 70% yield, which was dissolved in DME (1.20 cm³), and NaI (0.046

g, 0.31 mmol) and catalytic amount of AIBN were added. The mixture was refluxed and then was added nBu₃SnH (0.052 cm³, 0.18 mmol). After 1 h, the solvent was removed under reduced pressure, and the residue was purified by chromatography on silica gel (5% ethyl acetate/hexane) to afford (-)-**47** (0.022 g, 60%) as a colorless oil. [α]_D²⁰ -3.2 (c 0.34, CH₂Cl₂); IR ν_{\max} /cm⁻¹ 1697; ¹H NMR (300MHz; 55 °C; CDCl₃) δ 0.83 (d, *J* 7.0 Hz, 3H), 0.91 (d, *J* 6.6 Hz, 3H), 1.36-1.64 (m, 5H), 1.74-1.83 (br m, 1H), 2.02-2.18 (m, 1H), 2.78 (dt, *J* 2.8 and 12.5 Hz, 1H), 3.84 (br d, *J* 11.0 Hz, 1H), 4.08 (br d, *J* 12.5 Hz, 1H), 5.13 (s, 2H), 7.20-7.40 (m, 5H); ¹³C NMR (75.5 MHz; 55 °C; CDCl₃) δ 19.2, 19.3, 20.0, 25.6, 26.2, 26.3, 39.7, 57.6, 66.9, 127.8, 128.4, 137.5, 155.9; MS (EI): *m/z* 219 (5%), 218 (35%), 175 (8%), 174 (66%), 92 (8%), 91 (100%); HRMS (EI): found 261.1737; calc. for C₁₆H₂₃NO₂ [M]⁺ 261.1729.

Benzyl (2*R*)- 2- isopropylhexahydro- 1- pyridinecarboxylate [(+)-**47**]

The same procedure described above for (-)-**47** was employed starting with (+)-**48**. [α]_D²⁰ +3.0 (c 0.4, CH₂Cl₂).

(2'*S*)- 2- (1'- tert- butoxycarbonyl- hexahydro- pyridin- 2'-yl)- ethanoic acid (**50**)

The same procedure described above for the preparation of (-)-**44** was employed for **19** (0.23 g, 0.57 mmol). Recrystallization (Et₂O:Hexane) yielded (R)-4-benzyl-2-oxazolidinone (0.091 g, 95%) in yield. The residue from the ethyl acetate extract was purified by chromatography on silica gel (10% ethyl acetate/hexane) to afford **50** (0.12 g, 85%) as a white solid. IR ν_{\max} /cm⁻¹ 3467 (br), 3145, 1732, 1693; ¹H NMR (500 MHz; CDCl₃) δ 1.30-1.50 (m, 2H), 1.44 (s, 9H), 1.55-1.80 (m, 4H), 2.55 (dd, *J* 14.5 and 7.7 Hz, 1H), 2.62 (dd, *J* 7.4 and 14.5 Hz, 1H), 2.77 (br t, *J* 11.8 Hz, 1H), 3.99 (br d, *J* 11.8 Hz, 1H), 4.60-4.78 (br m, 1H), 5.5-6.5 (br m, 1H); ¹³C NMR (75.5 MHz; CDCl₃) δ 18.8, 25.1, 28.2, 28.3, 35.2, 39.2, 47.7, 80.0, 155.1, 176.5; MS (EI): *m/z* 187 (9%), 184 (6%), 170 (8%), 142 (17%), 129 (5%), 128 (75%), 84 (100%), 57 (66%); HRMS (EI): found 243.1471; calc. for C₁₂H₂₁NO₄ [M]⁺ 243.1470.

Methyl- 2- [(2'*S*)- 1'- (tert-butoxycarbonyl)- hexahydro- pyridin- 2'- yl] etanoate (**51**)

A solution of **50** (0.12 g, 0.48 mmol) in Et₂O (2.5 cm³) was treated with excess of an ethereal soln. of diazomethane. The solvent was evaporated and the crude mixture purified by chromatography on silica gel (5% ethyl acetate-hexane) to afforded **51** (0.12 g, 95%) as a colorless oil. [α]_D²⁰ -12.5

(*c* 4.8 in CHCl₃) [Lit¹⁹: [α]_D²⁰ -8.30 (*c* 5.5 in CHCl₃)]; IR ν_{max}/cm⁻¹ 1739, 1693; ¹H NMR (300 MHz; CDCl₃) δ 1.45 (s, 9H), 1.34-1.54 (m, 2H), 1.54-1.70 (m, 4H), 2.52 (dd, *J* 7.7 and 14.0 Hz, 1H), 2.60 (dd, *J* 7.4 and 14.0 Hz, 1H), 2.78 (br t, *J* 12.5 Hz, 1H), 3.66 (s, 3H), 3.90-4.06 (br m, 1H), 4.66-4.74 (br m, 1H); ¹³C NMR (75.5 MHz; 55 °C; CDCl₃) δ 18.8, 25.2, 28.2, 28.3, 35.0, 39.1, 47.8, 51.6, 79.5, 154.7, 171.9; MS (EI): *m/z* 184 (5%), 170 (5%), 156 (30%), 142 (26%), 128 (48%), 84 (100%), 57 (81%); HRMS (EI): found 201.1003; calc. for C₉H₁₅NO₄ [M-C₄H₈]⁺ 201.1001.

Methyl-(2R, 2'R)-2-(1'-benzyloxycarbonyl-hexahydro-pyridin-2'-yl)-2-phenylethanoic (68)

The same procedure described above for the preparation of (-)-**11** was employed for **56**, as a 12:1 mixture with **57** (0.29g, 0.57 mmol). Recrystallization (Et₂O:Hexane) yielded (S)-4-benzyl-2-oxazolidinone (0.091 g, 90%). The residue isolated from the ethyl acetate extract was purified by chromatography on silica gel (10% ethyl acetate/hexane) to afford the corresponding carboxylic acid **67** (0.17 g, 0.48 mmol). A solution of the above carboxylic acid (0.17 g, 0.48 mmol) in Et₂O (2.5 cm³) was treated with excess diazomethane in ether. The solution was evaporated and the crude mixture purified by chromatography on silica gel (15% ethyl acetate-hexane) to afford **68** (0.17 g, 81%) as a 12:1 mixture with its 2S epimer (determined by CGMS). Data for major **68**: [α]_D²⁰ -34.0 (*c* 1.5 in CH₂Cl₂); IR ν_{max}/cm⁻¹ 1738, 1699; ¹H NMR (300 MHz; 55 °C; CDCl₃) δ 1.20-1.80 (m, 6H), 3.09 (br t, *J* 12.5 Hz, 1H), 3.44 (s, 3H), 4.08-4.18 (m, 1H), 4.16 (d, *J* 11.7 Hz, 1H), 4.90-5.04 (m, 1H), 5.13 (d, *J* 12.5 Hz, 1H), 5.19 (d, *J* 12.5 Hz, 1H), 7.20-7.60 (m, 10H); ¹³C NMR (75.5 MHz; 55 °C; CDCl₃) δ 18.8, 25.3, 25.4, 39.7, 51.5, 51.7, 54.2, 67.2, 127.7, 127.8, 127.9, 128.2, 128.7, 128.9, 136.2, 137.2, 155.4, 172.1; MS (EI): 218 (27%), 175 (7%), 174 (47%), 121 (6%), 92 (8%), 91 (100%), 65 (6%); HRMS (EI): found 368.1864; calc. for C₂₂H₂₅NO₄ [MH]⁺ 368.1862.

(2R, 2'R)-2-(1'-Methoxycarbonyl-hexahydro-pyridin-2'-yl)-2-phenylethanoic acid (69)

The same procedure described above for the preparation of (-)-**11** was employed for **58** (0.25g, 0.57 mmol). Recrystallization (Et₂O:Hexane) yielded (S)-4-benzyl-2-oxazolidinone (0.091 g, 90%). The residue isolated from the ethyl acetate extract was purified by recrystallization (ethyl acetate:hexane) to yield **69** (0.14 g, 90%) as a white solid. [α]_D²⁰ -53.2 (*c* 1.4 in CH₂Cl₂); mp 154.6-155.0 °C; IR ν_{max}/cm⁻¹ 3162 (br), 3019, 1699; ¹H NMR (300 MHz; 55 °C; CDCl₃) δ 1.27-1.70 (m, 6H), 3.08 (br t, *J* 13.2 Hz,

1H), 3.66 (s, 3H), 4.02-4.18 (m, 1H), 4.14 (d, *J* 11.4 Hz, 1H), 4.82-5.04 (br m, 1H), 7.20-7.38 (m, 3H), 7.38-7.46 (br d, *J* 7.7 Hz, 2H), 8.22-8.60 (br s, 1H); ¹³C NMR (75.5 MHz; 55 °C; CDCl₃) δ 18.8, 25.2, 25.4, 39.7, 51.2, 52.7, 54.0, 127.8, 128.8, 128.9, 135.9, 156.5, 175.7. Found: C, 64.84; H, 7.02; N, 4.92. Calc. for C₁₅H₁₉NO₄ C, 64.97; H, 6.91; N, 5.05%.

(2R, 2'R)-Methylphenidate hydrochloride (66)

From **68**: To a solution of **68** (0.077g, 0.21mmol) in MeOH (2.6cm³) was added 10% Pd-C (0.03g). The resulting suspension was stirred 12 h at ambient temperature under hydrogen (1 atm). The reaction mixture was filtered through Celite, and the solvent was removed under reduced pressure. The residue was stirred overnight with ethanolic 2N HCl (2.0 cm³) at rt. Evaporation under reduced pressure and recrystallization (EtOH-Et₂O) of the crude solid afforded **66** (0.043g, 76%) as a white solid as a single isomer by ¹H and ¹³C NMR.

From **69**: A mixture of I₂ (0.058 g, 0.23mmol) and hexamethyldisilane (0.067 g, 0.46 mmol) was heated at 120 °C under argon with stirring until a colorless solution resulted (2 min). The solution was cooled to 25 °C and a solution of **69** (0.050 g, 0.18 mmol) in CH₂Cl₂ (0.5 cm³) was added. The mixture was stirred for 5 h at 25 °C, quenched with MeOH (1.0 cm³) and the red color was discharged with saturated aqueous sodium bisulphite. The solvent was removed under reduced pressure and the residue was taken up in ether (2.0 cm³) and treated with excess of an ethereal soln. of diazomethane. The solution was evaporated to a light yellow oil which was stirred overnight with ethanolic 2N HCl (2.0 cm³) at rt. Evaporation under reduced pressure and recrystallization (EtOH-Et₂O) of the crude solid afforded **66** (0.031g, 63%) as a white solid: mp 213.6-213.8 °C (lit^{15e}: 221-223 °C); [α]_D²⁰ +86.2 (*c* 1.0, MeOH) (lit²²: [α]_D²⁰ +88 (*c* 1.0, MeOH)); IR ν_{max}/cm⁻¹ 1739; ¹H NMR (300 MHz, CD₃OD) δ 1.20-1.45 (m, 3H), 1.45-1.90 (m, 3H), 3.02 (dt, *J* 3.3 and 12.8 Hz, 1H), 3.36 (br d, *J* 13.5 Hz, 1H), 3.63 (s, 3H), 3.74 (dt, *J* 2.6 and 10.6 Hz, 1H), 3.81 (d, *J* 9.9 Hz, 1H), 7.18-7.25 (m, 2H), 7.25-7.35 (m, 3H); ¹³C NMR (75.5 MHz; CD₃OD) δ 22.8, 23.4, 27.7, 46.7, 53.4, 55.3, 59.2, 129.6, 129.7, 130.4, 135.2, 173.3.

Acknowledgments

The authors wish to acknowledge FINEP, FAPESP, and CNPq for financial support and fellowships.

References

1. a) Overman, L. E.; Ricca, D. J. In *Comprehensive Organic Chemistry*, Trost, B. M.; Fleming, I., Eds; Pergamon Press: Oxford, 1991, vol. 2, p. 1007; b) Pilli, R. A.; Russowsky, D. *Trends in Org. Chem.* **1997**, *6*, 101; c) Arend, M.; Westermann, B.; Risch, N. *Angew. Chem. Int. Ed. Engl.* **1998**, *37*, 1045; d) Speckamp, W. N.; Moolenaar, J. M. *Tetrahedron* **2000**, *56*, 3817.
2. Evans, D. A.; Nelson, J. V.; Taber, T. R. in *Topics in Stereochemistry*, Allinger, N. L., Eliel, E. L., Wilen, S. H., Eds, John Wiley & Sons, **1982**, vol 3, p. 1.
3. a) Hiemstra, H.; Speckamp, W. N. In *Comprehensive Organic Synthesis*, Trost, B. M.; Fleming, I., Eds., Pergamon Press: Oxford 1991, vol. 2, p. 1047; b) de Koning, H.; Speckamp, W. N. In *Stereoselective Synthesis*, Helmchen, G.; Hoffmann, R. W.; Mulzer, J.; Schaumann, E., Eds., Houben-Weyl **1996**, vol E21, p. 1953.
4. a) Nagao, Y.; Daí, W.-M.; Ochiai, M. *Tetrahedron Lett.* **1988**, *29*, 6133; b) Arenz, T.; Frauenrath, H.; Raabe, G.; Zorn, M. *Liebigs Ann. Chem.* **1994**, 931.
5. Fuentes, L. M.; Shinkai, I.; Salzmann, T. N. *J. Am. Chem. Soc.* **1986**, *108*, 4675.
6. a) Nagao, Y.; Daí, W.-M.; Ochiai, M.; Tsukagoshi, S.; Fujita, E. *J. Am. Chem. Soc.* **1988**, *110*, 289; b) Nagao, Y.; Daí, W.-M.; Ochiai, M.; Tsukagoshi, S.; Fujita, E.; *J. Org. Chem.* **1990**, *55*, 1148; c) Nagao, Y.; Kumagai, T.; Nagase, Y.; Tamai, S.; Inoue, Y.; Shiro, M. *J. Org. Chem.* **1992**, *57*, 4232.
7. a) Evans, D. A.; Urpi, F.; Somers, T. C.; Clark, J. S.; Bilodeau, M. T. *J. Am. Chem. Soc.* **1990**, *112*, 8215; b) For a preliminary account of our work on the addition of titanium enolates of *N*-propionyl oxazolidin-2-ones to *N*-carboalkoxy- α -methoxy pyrrolidine and -piperidine, see Pilli, R. A.; Alves, C. F.; Böckelmann, M. A.; Mascarenhas, Y. P.; Nery, J. G.; Vencato, I. *Tetrahedron Lett.* **1999**, *40*, 2891; c) As this work was about to be concluded, a communication on the addition of the titanium(IV) enolate of *N*-phenylacetyl oxazolidin-2-ones to *N*-carbomethoxy- α -methoxypyrrolidine, -piperidine and -tetrahydroazepine appeared: Matsumura, Y.; Kanda, Y.; Shirai, K.; Onomura, O.; Maki, T. *Org. Lett.* **1999**, *2*, 175; d) Matsumura, Y.; Kanda, Y.; Shirai, J.; Onomura, O.; Maki, T. *Tetrahedron* **2000**, *56*, 7411.
8. For the utilization of this methodology in the stereoselective preparation of alkaloids, see: Pilli, R. A.; Russowsky, D. *J. Org. Chem.* **1996**, *61*, 3187.
9. a) Moody, C. J.; Taylor, R. J. *J. Chem. Soc. Perkin Trans I* **1989**, 721; b) Speckamp, W. N.; Hubert, J. C.; Wumberg, J. B. P. A. *Tetrahedron* **1975**, *31*, 1437.
10. Evans, D. A.; Bartroli, J.; Shih, T. L. *J. Am. Chem. Soc.* **1981**, *103*, 2127.
11. Analyses of the ^1H - and ^{13}C NMR spectra at room temperature of the adducts were precluded due to the presence of the corresponding rotamers. NMR analyses above room temperature restored baseline resolution allowing determination of the diastereoisomeric ratio.
12. Freshly prepared $n\text{-Bu}_2\text{BOTf}$ is required to reproduce yields and avoid partial nitrogen deprotection due to the presence of trace amounts of triflic acid.
13. Morley, C.; Knight, D. W.; Share, A. C. *J. Chem. Soc. Parkin Trans I* **1994**, 2903.
14. Patrick, K. S.; Caldwell, R. W.; Ferris, R. M.; Breese, G. R. *J. Pharmacol. Exp. Ther.* **1987**, *241*, 152.
15. For racemic syntheses of metilphenidate see, *inter alia*: a) Dias, L. C., Fernandes, A. M. A. P., *Synth. Commun.* **2000**, *30*, 1311. For asymmetric syntheses, see: b) Prashad, M.; Har, D.; Ropic, O.; Blacklock, T. J.; Giannousis, P. *Tetrahedron: Asymmetry* **1998**, *9*, 2133; c) Faulconbridge, S.; Zavareh, H.; Evans, G.; Langston, M. PCT Int. Appl. *Chem. Abstr.* **1998**, *129*, 67705; d) Langston, M.; Zavareh, H. PCT Int. Appl. *Chem. Abstr.* **1997**, *127*, 205477; e) Zavareh, H. PCT Int. Appl. *Chem. Abstr.* **1997**, *127*, 278144; f) Thai, D. L.; Sapko, M. T.; Reiter, C. T.; Bierer, D. E.; Perel, J. M. *J. Med. Chem.* **1998**, *41*, 591; g) Prashad, M.; Kim, H.; Lu, Y.; Har, D.; Repic, O.; Blacklock, T. J.; Giannousis, P. *J. Org. Chem.* **1999**, *64*, 1750; h) Davies, H. M. L.; Hansen, T.; Hopper, D. W.; Panaro, S. A. *J. Am. Chem. Soc.* **1999**, *121*, 6509; i) Axten, J. M.; Ivy, R.; Krim, L.; Winkler, J. D. *J. Am. Chem. Soc.* **1999**, *121*, 6511.
16. Gainetdinov, R. R.; Wetsel, W. C.; Jones, S. R.; Levin, E. D.; Jaber, M.; Caron, M. G. *Science* **1999**, *283*, 397.
17. Seebach, D.; Prelog, V. *Angew. Chem. Int. Ed. Engl.* **1982**, *21*, 654.
18. Perrin, D. P.; Armarego, W. L. F.; Perrin, D. R. *Purification of Laboratory Chemicals*, Pergamon Press, Oxford, 2nd Edition, 1985.
19. Ager, D. J.; Allen, D. R.; Scaad, D. R. *Synthesis* **1996**, 1283.
20. a) Gage, J. R.; Evans, D. A. *Org. Synth.* **1989**, *68*, 83; b) Evans, D. A.; Britton, T. C.; Dorow, R. L.; Dellaria, J. F. *Tetrahedron* **1988**, *44*, 5525.
21. Shono, T.; Matsumura, Y.; Tsubata, K.; *Org. Synth.* **1985**, *63*, 206.
22. Rometsch, R. US. Patent 2,957,880, October 25, 1960.

Received: January 24, 2001

Published on the web: August 15, 2001